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ABSTRACT 
 Sickle cell disease (SCD) is a common genetic blood disorders that is 
characterized by painful vaso-occlusive episodes (VOEs), which are the major 
cause of hospitalizations for these patients.  One of the mechanisms that may 
contribute to the development of painful VOEs is the imbalance between 
vasoconstrictors and vasodilators.  This thesis focuses on the vasoconstrictors 
endothelin-1 (ET-1), which is elevated during VOEs and is pro-nociceptive, and 
angiotensin II (Ang II) and the vasodilator apelin, which has anti-nociceptive 
properties.  This thesis tested two hypotheses: 1) an imbalance between the 
vasoconstrictive and pro-nociceptive systems and vasodilatory and anti-
nociceptive systems contributes to pain in children with SCD and 2) the pain 
associated with VOEs in SCD involves the contralateral sensitizing effects of ET-
1 through central mechanisms.  The first aim of this thesis explored the impact of 
an imbalance between apelin and either endothelin or Ang II on pain measures in 
children with SCD.  The second aim determined the pain neuroaxis location of 
the sensitizing/desensitizing effect of ET-1 and the effect of endothelin system 
activation on the apelin system.  The last aim explored associations between 
genetic variability in the apelin receptor gene and pain measures.  An imbalance 
between apelin and endothelin was correlated with underlying baseline pain and 
the frequency of VOEs while Ang II was correlated with acute procedural pain.  In 
our models of acute VOEs, the mechanism responsible for the contralateral 
vi 
sensitizing effect of ET-1 is, at least in part, mediated centrally in the spinal cord.  
In contrast, at the level of the primary afferent neuron, repeated exposure to ET-1 
has a desensitizing effect.  Furthermore in a sex-dependent manner, activation of 
the endothelin system decreased the peripheral apelin system with a 
concomitant increase in the central apelin system.  Single nucleotide 
polymorphisms in the apelin receptor gene in children with SCD had strong 
trends for associations with indirect pain measures, namely increases in health 
care utilization.  Overall, these results support the postulates that contralateral 
sensitizing effects of ET-1 occurs through central mechanisms in the spinal cord 
and that an imbalance between the vasoconstrictive and pronociceptive systems 
and vasodilatory and antinociceptive systems may contribute to pain associated 
with SCD.
vii 
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1.1 Sickle Cell Disease 
Sickle cell disease (SCD) is one of the most common genetic blood 
disorders. SCD results from a single nucleotide polymorphism (A to T) in the β-
globin gene that leads to the polymerization of hemoglobin S molecules (HbS) 
and eventually the formation of “sickle” shaped red blood cells upon 
deoxygenation (Figure 1.1).  It is estimated that approximately 70,000 to 100,000 
individuals in the United States have SCD (Hassell, 2010).  The healthcare costs 
associated with this chronic illness are estimated to be close to $1.1 billion 
annually in the U.S. and these costs do not factor in the loss of productivity and 
the diminished quality of life that accompany this disease (Kauf et al., 2009). 
1.1.1 Hemoglobinopathies associated with SCD 
There are several forms of SCD that differ in severity and 
pathophysiology.  The most common, and one of the most severe forms, is the 
HbSS (homozygous sickled hemoglobin) genotype or sickle cell anemia (SCA).  
It is estimated that in Africa, approximately 280,000 children are born with SCA 
each year (Makani et al., 2010).  The life expectancy for these patients is almost 
28 years below race-matched asymptomatic populations (Edwards et al., 2005).  
Other common forms include the HbSC and HbSβ+-thalassemia genotypes, 
which typically exhibit milder clinical symptoms, and the HbSβ0-thalassemia 
genotype, which is similar to HbSS in severity (Serjeant, 2013).   
  Fetal hemoglobin (HbF) is usually produced in the first two years of life 
and is the predominant form of hemoglobin for the first two months, and it is 
associated with protection from the adverse effects of the HbS allele (Schnog et 
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al., 2004; Steinberg, 2005; Akinsheye et al., 2011).  Patients with a higher 
percentage of HbF typically have lower rates of mortality and a lower frequency 
of painful VOEs compared to patients with a lower percentage of HbF, and 
patients with persistent HbF (>20%) usually show no complications related to 
SCD (Schnog et al., 2004).  Although HbF is produced during the first two years 
of life, the levels dramatically decrease over the first six months after birth (Edoh 
et al., 2006).  The decrease in HbF corresponds with the appearance of clinical 
symptoms in children with SCD, which can occur as early as 6-12 months of age 
(Steinberg, 1999). 
1.1.2 Clinical Symptoms 
 
SCD is a multifaceted disease that has many clinical complications.  
These complications can include anemia, stroke, multi-organ damage, acute 
chest syndrome, and recurrent painful vaso-occlusive crises (VOEs).  Acute 
chest syndrome (ACS) is one of the leading causes of hospitalization and death 
in SCD patients (Schnog et al., 2004).  It is characterized by fever, shortness of 
breath, and chest pain and is thought to be caused by fat or thrombotic embolism 
and occlusion in the pulmonary vasculature (Schnog et al., 2004).  The risk 
factors associated with ACS include having the HbSS genotype, lower levels of 
fetal hemoglobin, and previous episodes of ACS (Schnog et al., 2004; Stuart and 
Nagel, 2004).   
Vaso-occlusive episodes (VOEs) are the hallmark features of SCD.  Vaso-
occlusion is caused by the polymerization of HbS (sickled hemoglobin) after 
deoxygenation, which leads to rigid sickled shaped red blood cells (SS-RBCs) 
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that become occluded in the microvasculature (Figure 1.2).  Occlusion of the 
blood vessels leads to hypoxia, ischemia, tissue damage, inflammation of the 
vasculature, and extreme pain (Ballas et al., 2012).  Occlusion in small and large 
blood vessels in the brain can lead to brain injury, such as stroke, in some 
patients, especially young children (Moser et al., 1996).  On average, SCD 
patients have about 2 episodes per year that require health care utilization and 
approximately 17% of patients have more than 3 crises per year (Smith and 
Scherer, 2010). 
1.2 Vaso-occlusion in SCD 
1.2.1 Vascular component 
 Vaso-occlusion in SCD is a complicated process that depends on many 
factors such as physical obstruction of blood vessels by SS-RBCs, adhesion of 
blood cells to the endothelium, as well as imbalances in vasomotor tone that lead 
to reduced blood flow (Ergul et al., 2004; Chiang and Frenette, 2005).  Occlusion 
of the blood vessels leads to localized ischemia, which results in tissue damage, 
which in turn leads to pain through the release of certain molecular mediators 
(Stinson and Naser, 2003).  The interactions between the SS-RBCs and the 
endothelium are thought to contribute to vaso-occlusion through several different 
mechanisms including disturbing the balance between vasoconstrictors and 
vasodilators in the vessels (Ergul et al., 2004).  The endothelium produces many 
vasoactive compunds involved in constriction and dilation, such as endothelins 
and nitric oxide (NO) (Graido-Gonzalez et al., 1998).  In SCD, both 
vasoconstrictors and vasodilators are upregulated, and this upregulation along 
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with an impairment in NO-dependent vasodilation leads to vascular instability 
(Nath et al., 2004). 
1.2.2 Pain component 
 It is believed that the release of chemical mediators, such as inflammatory 
mediators, from the endothelium lead to activation of nociceptors, which are 
nerve fibers responsible for transmitting pain signals (Stuart and Nagel, 2004).  
Acute painful crises occurs in approximately 70% of patients and is responsible 
for 90% of hospital admissions for adult SCD patients, but the frequency of these 
crises is highly variable among patients (Steinberg, 1999; Ballas, 2005).  The 
duration of the painful crisis can also vary considerably between patients, but on 
average, patients report a duration of 4 or 5 days; however, for some patients, it 
can last for up to 2-3 weeks (Stinson and Naser, 2003).   In one study examining 
children and adolescents with SCD,  older adolescents typically reported a longer 
duration of pain episodes, than younger children (Shapiro et al., 1995).  The 
areas most commonly affected during a painful crisis are the chest, back, 
abdomen, and the extremities, and typically, multiple areas are involved 
simultaneously (Steinberg, 1999).  The pain is often described as “throbbing”, 
“sharp”, “dull”, “stabbing”, and “shooting”, and some of these descriptors, such as 
“stabbing” and “shooting” indicate a neuropathic pain component and suggest 
that central as well as peripheral mechanisms may be involved (Ballas, 2005; 
Smith and Scherer, 2010). 
 Although patients on average have about  2 crises per year, one study 
reported that adults with SCD experienced SCD pain on 54.5% of the 31,017 
6 
days surveyed (Smith et al., 2008).  Another study found that children and 
adolescents reported SCD pain on 8.4% of the 1,515 days surveyed (Dampier et 
al., 2002).  These reports suggest that although acute pain is the hallmark 
complication of vaso-occlusion, this pain can become more chronic in nature in 
adults, which may possibly be due to peripheral or central sensitization. 
 Nociceptive pain involves: 1.) the transduction of signals from mechanical, 
thermal, or chemical stimuli into nerve impulses through primary afferent 
nociceptors, 2.) transmission of these signals to second order neurons in the 
spinal cord then eventually to higher brain centers, 3.) modulation of these 
signals in the dorsal horn of the spinal cord and input from ascending and 
descending pathways, and 4.) perception of the nociceptive signal due higher 
brain centers (Figure 1.3).  The source of nociceptive pain in SCD most likely 
includes chemical stimuli such as substance P, calcitonin gene-related peptide 
(CGRP), bradykinin, and prostaglandins that are produced after ischemic tissue 
damage, which in turn activate or sensitize nociceptors in the damaged tissue 
(Ballas, 2005).   
1.3 Vascular regulation in SCD 
 Another component besides interactions of SS-RBCs with the endothelium 
that contributes to VOEs may be the dysregulation of vasomotor tone.  Patients 
with SCD show impairment in endothelium-dependent vasodilation, and the 
amount of NO production under basal conditions in these patients is similar or 
lower than healthy controls (Belhassen et al., 2001).  In a transgenic mouse 
model of sickle cell disease, vascular responses to vasodilators are altered, and 
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when vasodilatory components that help produce nitric oxide synthase (NOS), 
the molecule responsible for producing NO, are inhibited, an overactive 
vasoconstrictive system is revealed (Nath et al., 2000).  These results suggest 
that there is some impairment in vascular regulation in SCD.  It has been 
speculated that occlusion in one part of the blood vessel leads to the release of 
certain vasoactive substances from damaged endothelial cells, such as 
vasoconstrictive peptides that promote vaso-occlusion downstream from the 
original site of vaso-occlusion (Kaul et al., 1996).  It may also be possible that 
vasoactive humoral factors could be responsible for the extension of pain from 
the original site of painful crisis (Kaul et al., 1996).  We believe that it is the 
vasoactive and nociceptive actions of endothelin-1, a potent vasoconstrictive and 
nociceptive agent, that are some of the factors responsible for this phenomenon. 
1.4 Role of Vascular Regulators in Pain 
1.4.1 Vasoconstrictor: Endothelin-1  
Endothelin-1 (ET-1) was identified in 1988 as a potent vasoconstrictor 
(Yanagisawa et al., 1988; Rubanyi and Polokoff, 1994).  ET-1 is a 21 amino acid 
peptide that is formed from the 39 amino acid precursor peptide Big Endothelin 
(Big ET) by endothelin converting enzyme (Figure 1.4).  Unexpectedly in early 
human studies, administration of ET-1 produced severe and long lasting pain 
(Dahlof et al., 1990).  This discovery led to the investigation of ET-1 as a 
potential pain mediator. Further studies, identified elevated plasma ET-1 levels in 
many disease states in which pain is a major symptom, such as VOEs and ACS 
in SCD (Hammerman et al., 1997; Graido-Gonzalez et al., 1998).   
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In VOEs associated with SCD, the time course of elevated ET-1 plasma 
levels parallels the temporal profile of pain in these patients (Hammerman et al., 
1997; Graido-Gonzalez et al., 1998; Rybicki and Benjamin, 1998; Ergul et al., 
2004; Tharaux et al., 2005).  Furthermore, down-regulation of ET-1 gene 
expression has been found in SCD patients treated with hydroxyurea (HU), which 
is a drug that has been shown to decrease the rate and intensity of VOEs (Brun 
et al., 2003; Odievre et al., 2007).  HU has been shown to reduce in half the 
levels of circulating ET-1 in children with SCD (Lapoumeroulie et al., 2005).  The 
induction of ET-1 mRNA and the release of ET-1 from endothelial cells are 
stimulated by sickled red blood cells from homozygous sickle cell (HbSS) 
patients (Phelan et al., 1995; Shiu et al., 2002).  This provides further evidence 
that ET-1 may be an important factor in facilitating vaso-occlusive episodes.  
Increased production of ET-1 has been shown in endothelial cells exposed to 
plasma from SCD patients during acute chest syndrome (ACS).  The highest 
levels of ET-1 stimulation came from  plasma samples that were taken four days 
prior to hospital admittance for VOEs (Hammerman et al., 1997).   
Many different cells produce ET-1 including endothelial cells, vascular 
smooth muscle cells (Lerman et al., 1991), cardiac myocytes (Suzuki et al., 1993; 
Harada et al., 1997), neurons (Hasue et al., 2005), mast cells (Liu et al., 1998), 
and macrophages (Ehrenreich et al., 1990).  Both physiological and 
pathophysiological mediators modulate the synthesis and release of ET-1.  Nitric 
oxide and prostacyclin are two well-studied mediators which inhibit the 
production of ET-1 (Kopetz et al., 2002).  In contrast, pro-inflammatory cytokines, 
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angiotensin II, norepinephrine, bradykinin, mechanical stress, peripheral tissue 
injury, and hypoxia stimulate the production of ET-1 (Moreau et al., 1997; Ahn et 
al., 1998; Carducci and Jimeno, 2006).  Within the vasculature, ET-1 release 
from endothelial cells is polarized with release being toward the smooth muscle 
interface. This suggests that plasma ET-1 elevations after vascular injury most 
likely result from spill-over from the smooth muscle as opposed to it being from 
the circulation  (Wagner et al., 1992).   
ET-1 exerts its effects through two G-protein coupled receptors, the ETA 
and ETB receptors.  Binding of ET-1 to the ETA and ETB receptors located on 
vascular smooth muscle cells leads to vasoconstriction. In contrast, binding of 
ET-1 to ETB receptors located on the endothelium leads to the synthesis of 
vasodilators such as NO (Bourque et al., 2011).  Similarly, in pain modulation the 
two receptors are thought to variably regulate the pain response depending upon 
the tissue in which the receptors are expressed. 
The endothelin system is has been identified at all levels of the pain 
signaling pathway.  Peripheral endings of nociceptors are located in the 
epidermis of the skin and have been shown to be modulated by the local 
endothelin system.  ETB receptors have been identified on endothelial cells 
(Ghoneim et al., 1993), smooth muscle cells (Shetty et al., 1993), macrophages 
(Sakurai-Yamashita et al., 1997), and keratinocytes within the dermis and 
epidermis of the skin. In the DRG, ETB receptors have been identified on satellite 
glial cells and Schwann cells that myelinate nociceptors, but not on nociceptors 
(Pomonis et al., 2001; Berti-Mattera et al., 2006; Chichorro et al., 2010).  ETA 
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receptors have been identified on the peripheral endings of the nociceptors, on 
nerve axons, and the nociceptors cell bodies located in the dorsal root ganglion 
(DRG) (Pomonis et al., 2001).  In the DRG, ETA receptors are expressed in 
small, medium, and large-sized nociceptors (Chichorro et al., 2010).  Within the 
brain, ETA receptors have been identified in the hypothalamus, reticular 
formation, pontine tegmentum, locus coeruleus, and substantia nigra (Kurokawa 
et al., 1997; Yamada and Kurokawa, 1998). ET-1 is expressed in the epidermis 
and in laminae I-V of the spinal cord (Yoshizawa et al., 1989).  Similar to the 
opposite effects observed for the vasculature, the endothelin receptors also show 
opposite effects on pain processing depending on the location and the pain 
model.  Activation of ETA receptors typically induces nociception while activation 
of the ETB receptor typically leads to anti-nociception (Gokin et al., 2001; 
Khodorova et al., 2002; Khodorova et al., 2003).  In summary, the endothelin 
system is functional across the pain neuroaxis and likely participates in signaling 
cascades which can modulate acute and chronic pain. 
Following injection into the human forearm, ET-1 was found to cause 
acute pain and sensitization to mechanical and other noxious stimulation 
(Ferreira et al., 1989; Dahlof et al., 1990; Hans et al., 2007).  Similarly in rodents, 
injection of ET-1 into the hindpaw or directly onto the sciatic nerve elicits 
spontaneous nociceptive behaviors (Davar et al., 1998; Gokin et al., 2001).  
These spontaneous nociceptive behaviors are age and sex dependent (McKelvy 
et al., 2007).  Significantly greater nociceptive behaviors have been reported in 
younger animals and decrease with age.  In addition, clear sex differences have 
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been observed at early ages, with increased nociception in males compared to 
females.  These sex differences appear to decrease with maturation.  Similarly, 
nociceptive priming effects of ET-1 demonstrate both age- and sex-dependence. 
The priming effect of ET-1 produces altered nociceptive behaviors in response to 
a second exposure to ET-1 when compared to a first exposure. In neonatal rats, 
priming with ET-1 increased subsequent nociceptive behaviors in males but 
decreased behaviors in females. (McKelvy and Sweitzer, 2009).  This is likely 
important in certain disease states, such as sickle cell disease, in which there is 
repeated exposures to ET-1.  
1.4.2 Vasoconstrictor: Angiotensin II 
Similar to ET-1, angiotensin II (Ang II) is a potent vasoconstrictor and 
plays an important role in the regulation of vasomotor tone (Nguyen Dinh Cat and 
Touyz, 2011). The actions of Ang II are mediated by two G protein coupled 
receptors: AT1 and AT2.  The vasoconstrictive properties of Ang II are mediated 
by binding to the AT1 receptor.  In contrast, lower affinity binding to the AT2 
receptors functions as a negative feedback to induce vasodilation (Nguyen Dinh 
Cat and Touyz, 2011).  In addition to its roles in the cardiovascular system, Ang II 
may also play a role in pain processing or modulation.  It has been documented 
that Ang II and its receptors are produced in parts of the pain neuroaxis and may 
contribute to the development of pain hypersensitivity (Chakrabarty et al., 2008; 
Imboden et al., 2009; Chakrabarty et al., 2013).  Depending on whether Ang II is 
injected peripherally or centrally, the particular pain model, or the species it can 
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be either anti-nociceptive or nociceptive (Irvine and White, 1997; Georgieva and 
Georgiev, 1999; Marques-Lopes et al., 2009). 
 
1.4.3 Vasodilator: Apelin 
Apelin is a recently discovered peptide that has been many different 
physiological effects throughout the body.  It was first isolated from bovine 
stomach tissue in 1998 by Tatemoto et al. and was found to be the endogenous 
ligand for the orphan G-protein coupled receptor, APJ.  Apelin is formed from a 
77 amino acid preproapelin, which is cleaved by angiotensin-converting enzyme 
2 to form apelin-36 and other small biologically active fragments such as apelin-
13 and apelin-12 (Cheng et al., 2012).  The APJ receptor is a G-protein coupled 
receptor that couples to Gαi/o to inhibit the activity of adenylyl cyclase and cause 
the phosphorylation of ERK1/2 when activated (O'Carroll et al., 2013).  Apelin 
and its receptor are found throughout the body and they are involved in several 
functions including, but not limited to, the regulation of cardiovascular and body 
fluid homeostasis (Barnes et al., 2010).  In the vasculature, apelin, through its 
interaction with the APJ receptor, causes NO-dependent vasodilation when 
acting on endothelial cells and vasoconstriction when acting directly on smooth 
muscle cells, suggesting that it may play an important role in the maintenance of 
vascular tone (Kleinz et al., 2005; Japp et al., 2008; Maguire et al., 2009).   
In addition to its location in the vasculature, apelin has been found in the 
nerve fibers of neurons in several key areas of the central nervous system 
involved in the nociceptive pathway such as the periaqueductal grey and dorsal 
13 
raphe nucleus (Reaux et al., 2002).  In the rat, APJ receptors have been found in 
both neuronal and glial cells in the central nervous system (Medhurst et al., 
2003).  Recently, apelin has been shown to have a modulatory role in 
nociception.  When injected centrally, apelin-13 has anti-nociceptive effects in 
both a visceral and acute pain model, which is thought to occur through both the 
APJ and µ-opioid receptors (Xu et al., 2009; Lv et al., 2012).  Mice lacking the 
gene for apelin have lower thresholds for thermal nociception compared to wild-
type mice, which further suggests that apelin may play a role in pain processing 
or modulation (Kasai et al., 2011).  Currently, the involvement of apelin in the 
pain associated with SCD is unknown. 
1.5 Previous Results 
Previously, we have shown that ET-1 in the plasma of children with SCD 
is related to baseline pain, suggesting a role for ET-1 in existing vaso-occlusive 
pain (Schlenz et al., 2012).  Since ET-1 appears to play a role in VOEs and also 
elicits nociception in both humans and animals, our lab uses it to model an acute 
VOE in the rat hindpaw.  We have previously shown that repeated 
administrations of ET-1 into the same hindpaw elicit a sex dependent response, 
with males exhibiting sensitization and females exhibiting desensitization; 
however, when the second administration is given in the opposite hindpaw as the 
first administration, both sexes exhibit sensitization.  What is unknown is whether 
or not this contralateral sensitization is specific for ET-1 and the location of this 
sensitizing effect. 
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Building upon these previous results, this dissertation seeks to explore 1) 
if ET-1 produces a systemic pain sensitization to other algogens and 2) the 
balance between pronociceptive ET-1 and potentially antinociceptive and 
vasodilatory apelin peptide in the pain associated with SCD. 
1.6 Hypothesis 
This thesis will test two hypotheses: 1) an imbalance between the 
vasoconstrictive and pro-nociceptive systems and vasodilatory and anti-
nociceptive systems contributes to pain in children with SCD and 2) the pain 
associated with VOEs in SCD involves the contralateral sensitizing effects of ET-
1 through central mechanisms. 
1.7 Specific Aims 
Specific Aim 1: To determine the impact of the balance between 
vasoconstrictive and pronociceptive regulators (endothelin and 
angiotensin II) and vasodilatory and antinociceptive apelin on pain in 
pediatric SCD patients. 
Specific Aim 2: To determine whether the sensitizing/desensitizing effect of ET-
1 is specific for ET-1 and is mediated centrally (spinal cord) or at the level 
of the primary afferent neuron and to determine the effect of endothelin 
system activation on the apelin system. 
Specific Aim 3: To examine the apelin system separately in pediatric SCD 
patients focusing on the genetic variability within the apelin receptor gene. 
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Figure 1.1 Sickle cell disease: From the genetic to the tissue level.  Figure 
adapted from “A case study of the effects of mutation: Sickle cell anemia” 
Understanding Evolution. University of California Museum of Paleontology. 02 
May 2014 <http://evolution.berkeley.edu/evolibrary/article/mutations_06>. 
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Figure 1.2 Vaso-occlusion due to sickle-shaped red blood cells.  In small 
blood vessels, normal red blood cells can flow easily through the vessel.  
However, sickle-shaped red blood cells (RBC) are more rigid and more readily 
adhere to the endothelium, thereby causing occlusion of the vessel. 
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Figure 1.3 Physiology of pain Outlines the four stages of pain processing: 1) 
Transduction: translation of a mechanical, chemical, or thermal signal into an 
electrical impulse, 2) Transmission: process of by which the impulse is sent to 
the spinal cord and to the brain, 3) Modulation: dampening or amplification of the 
impulse due to ascending or descending inputs usually into the spinal cord, and 
4) Perception: the conscious awareness of pain due to the integration of the 
other three stages of pain processing 
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Figure 1.4 Conversion of Big ET to ET-1.  The 39 amino acid peptide Big ET is 
converted to the 21 amino acid peptide ET-1 by endothelin converting enzyme.  
The plasma half-life of Big ET is estimated to be around 23 minutes while the 
half-life of ET-1 is estimated to be between 1 and 2 minutes. 
 1Smith T, Schlenz A, Schatz J, Sweitzer SM. Modulation of Pain in Pediatric 
Sickle Cell Disease: Understanding the Balance between ET mediated 
vasoconstriction and apelin mediated vasodilation.  To be submitted to 
Blood Cells, Molecules and Diseases 
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CHAPTER 2: 
 
Modulation of Pain in Pediatric Sickle Cell Disease: Understanding 
the Balance Between ET Mediated Vasoconstriction and Apelin 
Mediated Vasodilation1 
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2.1 Introduction 
   Studies have shown that ET-1 levels are increased in SCD patients 
compared to healthy controls (Graido-Gonzalez et al., 1998; Werdehoff et al., 
1998) and these increased levels are even more pronounced during an acute 
VOE (Ergul et al., 2004).  Interestingly, the time course of ET-1 plasma 
elevations parallels VOE-associated pain symptoms with a peak in plasma levels 
and pain at the height of the VOE and then slow return to baseline that requires 
several weeks (Graido-Gonzalez et al., 1998).  In addition to its vasoactive 
properties, ET-1 also causes nociception when injected into both humans and 
animals (Ferreira et al., 1989; Dahlof et al., 1990; Davar et al., 1998; Gokin et al., 
2001; Hans et al., 2007; McKelvy et al., 2007; Smith et al., 2014).    
Previously, we have shown that endothelin variables in the plasma of 
pediatric SCD patients is related to baseline pain such that higher plasma levels 
of ET-1 were found in children with higher baseline pain (Schlenz et al., 2012).    
In contrast, lower plasma levels of Big ET, the precursor to ET-1, were found in 
children with a higher frequency of recent VOEs possibly a result of recent 
conversion to vasoactive ET-1.  From these findings of excessive endothelin 
mediated vasoconstriction in children with SCD, we were interested in the role of 
vasodilatory systems in SCD.  We have recently begun to explore the role of 
apelin, a novel vasoactive peptide with vasodilatory properties, in the pain 
associated with SCD.   
Apelin (Tatemoto et al., 1998) is formed from the 77 amino acid 
preproapelin, which is cleaved by angiotensin-converting enzyme 2 to form 
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apelin-36 and other biologically active fragments such as apelin-17 and apelin-13 
(Cheng et al., 2012).  Apelin is the endogenous ligand for the orphan G-protein 
coupled receptor, APJ.  In addition to its role in the vasculature, the apelin-APJ 
system has also been recently implicated in having a modulatory role in 
nociception since apelin and its receptor are found in several brain regions 
associated with pain (Xu et al., 2009; Kasai et al., 2011; Lv et al., 2012).  In the 
vasculature, apelin’s interaction with its receptor causes nitric-oxide (NO) 
dependent vasodilation when acting on endothelial cells (Japp et al., 2008; 
Maguire et al., 2009).  Recently, it has been proposed that there is a shift in favor 
of ET-1-mediated vasoconstriction and away from NO-mediated vasodilation 
during an acute VOE in SCD patients (Ergul et al., 2004).   
To date, there have been no studies that explore the potential relationship 
between apelin and ET-1 in the pain associated with SCD.  The general 
hypothesis of this work is that an imbalance between the vasoconstrictive and 
pronociceptive systems and vasodilatory and antinociceptive systems modulate 
SCD-associated pain.  The goal of this study was to examine the balance 
between ET-1 or its precursor, Big ET, and apelin in a cohort of pediatric SCD 
patients and how this balance correlates with acute chest syndrome (ACS), 
procedural pain, and pain history. 
2.2 Methods 
2.2.1 Participants 
 This study used a subsample of 47 children with SCD ages 2 to 18 (m = 
9.98, SD = 4.78; 22 male, 25 female) that were participating in a larger study of 
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procedural pain in SCD.  Due to the goals of the larger study, children between 
the ages of 10 and 12 (the transition from pre- to post-pubescence) were 
excluded.  Forty-seven children had adequate plasma available for apelin 
analysis by ELISA.  For the ratios, 46 children had both ET-1 and apelin data and 
43 children had both Big ET and apelin data available.  The ET-1 and Big ET 
ELISAs were conducted as part of the previous study and details about those 
results can be found in Schlenz, et al. (2012). For the child ratings reported 
below, only children over the age of 5 completed ratings, resulting in a sample of 
37 children for the apelin/ET-1 analysis and 36 children for the apelin/Big ET 
analysis. 
2.2.2 Procedures 
 Children and their caregivers were approached at routine hematologist 
visits for participation.  Children commonly receive routine venipuncture at these 
visits.  Venipuncture was chosen to represent a standardized painful stimulus.  
After consent and assent procedures were completed, children and caregivers 
completed baseline (pre-venipuncture) ratings of pain and caregivers completed 
a background questionnaire.  Once the venipuncture was completed, children 
and caregivers completed ratings of the child’s pain during the procedure.  
Children were also video recorded from the time they entered the exam room to 
the end of the venipuncture, in order to obtain observational ratings of pain.  
Medical record reviews were conducted after the child’s visit using a structured 
coding method. 
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2.2.3 Background and medical information 
 Caregivers completed a background information questionnaire to obtain 
demographic information.  Children rated their pain using the Wong Baker Faces 
Scale. Caregivers rated their child’s pain using a visual analog scale (VAS).  
Observational ratings of pain were also taken at baseline and during the 
procedure using the modified version of the Observational Scale of Behavioral 
Distress.  Reviews of children’s medical charts were used to establish history of 
ACS, VOEs, and SCD genotype.  Of the 47 children in this sample, 12 had a 
history of acute chest syndrome and 35 did not.  For recent VOE history, we 
measured the number of hospitalizations, emergency department visits, and 
outpatient contacts for pain in the previous 24 months.  The SCD genotypes 
were divided into the more severe phenotype (HbSS and HbSβ°) and more mild-
moderate phenotype (HbSC and HbSβ+).  Of the 47 children, 34 were 
categorized as having the more severe phenotype and 13 were categorized as 
having the more mild-moderate phenotype for the apelin levels and apelin to ET-
1 ratio and 33 severe and 11 mild to moderate for the apelin to Big ET ratio. 
2.2.4 ELISA 
 Blood collection and plasma separation for this sample of participants has 
been described previously (Schlenz et al., 2012).  Briefly, blood was collected 
into EDTA vacutainer tubes and placed on ice for plasma isolation within 30 
minutes of blood collection.  After isolation, plasma was stored at -80°C until 
further analysis by ELISA.  ELISA kits for ET (1-21) (Cat no. Bl-20052) and Big 
ET (Cat no. Bl-20082) were purchased from ALPCO Immunoassays and apelin-
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36 (EK-057-15) was purchased from Phoenix Pharmaceuticals.  ELISAs for ET-1 
and Big ET-1 were performed in triplicate and ELISAs for apelin-36 were 
performed in duplicate according to the respective assay protocols.  A standard 
curve was plotted from the standards of each kit using Prism software (GraphPad 
Software Inc, San Diego, CA), which was then used to extrapolate the sample 
concentrations from each plasma sample. 
2.2.5 Data analysis 
 This study used an exploratory analysis to examine relationships between 
apelin and ratios of apelin to ET-1 and Big ET to the primary outcomes: baseline 
pain, procedural pain, acute chest syndrome and recent VOE history.  For VOE 
history, there was one outlier (a child with 58 documented pain episodes) who 
was removed from analysis.  The relationships between apelin, the two ratios, 
baseline pain, procedural pain, and VOE history were assessed using 
correlations. The relationship between apelin, the two ratios, ACS, and disease 
severity were assessed via t-test.  Descriptive information on age and gender 
differences for apelin is also provided using correlation and t-test analysis, 
respectively. Information on age and gender for ET-1 and Big ET can be found in 
a prior publication (Schlenz et al., 2012).  
 The ratio variables demonstrated a positive skew that was corrected with 
log-transformation.  Additionally, to ensure that the ratios were equally 
associated with both apelin and the endothelin variables, we examined 
correlations between the ratios, apelin, ET-1, and Big ET.  The log-transformed 
ratio for apelin/ET-1 was highly associated with ET-1 (r = -.84) whereas the 
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untransformed ratio was more equally associated with both apelin (r = .41) and 
ET-1 (r = -.47). Both the log-transformed and untransformed results can be found 
in Table 1. For outcome variables, the three baseline and procedural pain ratings 
all demonstrated a positively skewed distribution and were log-transformed. In 
addition, because baseline ratings of pain were associated with significantly 
greater procedural pain, regression was used to remove variance in procedural 
pain that could be explained by baseline ratings. This approach allowed for the 
procedural pain ratings to solely reflect pain from the procedure. Finally, due to 
the exploratory nature of this study, we were careful to evaluate the impact of 
outliers (defined as values exceeding three standard deviations from the mean of 
the variable). 
2.3 Results 
 Table 2.1 provides correlation results and these findings are explained 
descriptively below.  Apelin plasma levels had a range of 0.87 to 10.74 ng/mL (m 
= 2.74; SD = 1.73).  The ranges for plasma ET-1 and Big ET were 0.21 to 4.25 
pg/mL (excluding the children whose levels exceeded 10 pg/mL) and 0.0 to 1.57 
pg/mL (m = 0.93, m = 0.39; SD = 0.96, SD = 0.30), respectively. 
2.3.1 Demographics 
 Apelin was significantly related to age, with older age children displaying 
lower plasma apelin levels.  There was no statistically significant difference in 
mean apelin levels between male (m = 2.53, SD = 1.42) and female (m = 2.61, 
SD = 1.12) children.  There were also no significant differences in the ratio data 
between male and female children.  
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2.3.2 Correlation with pain measures 
 Apelin alone was not significantly related to any of the baseline pain 
ratings (caregiver, child, or observational), procedural pain ratings, or recent VOE 
history.  The apelin/ET-1 ratio was not significantly related to procedural pain or 
recent VOE history.  However, the apelin/ET-1 ratio was negatively correlated to 
observational baseline pain ratings (r = -0.32, p = 0.032) (Figure 2.1).  The 
apelin/Big ET ratio was significantly correlated with caregiver ratings of baseline 
pain (r = -.30, p = .049) and approached significance in relation to child ratings of 
baseline pain (r = -.29, p = .088). The apelin/Big ET ratio was not significantly 
related to the remaining baseline and procedural pain variables or VOE history.  
However, when the same outlier noted above for VOE history was removed, a 
statistically significant correlation was found between the apelin/Big ET ratio and 
VOE history, r = .32, p = .041 (Figure 2.2).  
2.3.3 Relationship to ACS  
 There was no statistically significant difference in apelin levels between 
children with (m = 2.20, SD = .91) and without (m = 2.71, SD = 1.37) a history of 
acute chest syndrome, p = .221.  There was also no statistically significant 
difference in apelin/ET-1 ratio values for children with (m = 5.87, SD = 5.58) and 
without (m = 4.22, SD = 4.11) a history of acute chest syndrome, p = .282. There 
was also no significant difference in apelin/Big ET ratio values for children with 
(m = .93, SD = .35) and without (m = .79, SD = .36) a history of acute chest 
syndrome, p = .257.  
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2.3.4 Relationship to disease severity 
 There were no significant differences found between the more severe 
disease phenotypes and the more mild-moderate phenotypes for either the 
plasma apelin levels (p = 0.5302) or the apelin/ET-1 ratio (p = 0.5961). There 
was a trend for a significant difference between the severe and mild-moderate 
phenotype for the apelin/Big ET ratio (p = 0.079) (Figure 2.3). 
2.3.5 Relationship of apelin to ET-1 and Big ET 
 There was a significant positive correlation between plasma apelin levels 
and ET-1 levels (p = 0.0478, r = 0.290).  No significant correlation was found 
between apelin and Big ET. 
2.4 Discussion 
  In this study we sought to examine vasodilatory and antinociceptive 
plasma apelin expression in children with SCD.  In addition, this study sought to 
determine how the balance between vasodilatory apelin and vasoconstrictive 
endothelin plasma levels impacts pain reports in children with SCD.  Plasma 
apelin expression was related to age, with decreased levels as a child ages, but 
no relationship was found between apelin and baseline pain, procedural pain, or 
history of recent VOEs.  Similarly, the ratio between apelin and ET-1 was not 
related to procedural pain or recent VOEs, but it was negatively correlated to 
observational baseline pain.  In contrast, the ratio between apelin and Big ET 
was found to positively correlate to history of VOEs such that increased ratios of 
the two peptides was associated with an increased number of VOEs.   The 
results from this study suggest that an imbalance in the apelin and endothelin 
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systems may contribute to an increasing number of VOEs and baseline pain in 
children with SCD.  This is the first study that has demonstrated a potential 
relationship between the apelin and endothelin systems in VOEs, which are one 
of the hallmark complications associated with SCD. 
Vascular tone is maintained by a delicate balance of vasoconstrictors and 
vasodilators, and in diseases like SCD, it is believed that there is an imbalance in 
these systems that may further contribute to vaso-occlusion and the pain 
associated with vaso-occlusion (Nath et al., 2000; Ergul et al., 2004).  Our 
previous work has shown that increased plasma endothelin levels were more 
closely associated with greater baseline pain in children with SCD (Schlenz et al., 
2012).  In humans, intravenous infusion of apelin into arteries causes endothelial 
NO-mediated vasodilation (Japp et al., 2008).  In the vasculature, binding of 
apelin to the APJ receptor produces NO dependent vasodilation (Japp et al., 
2008; Maguire et al., 2009).  Impairment in endothelium-dependent vasodilation 
with decreased  NO production under basal conditions and during times of wall 
shear stress such as experienced during a VOE has been reported in patients 
with SCD (Belhassen et al., 2001).  These current findings are the first to suggest 
that impairment in endothelium-dependent vasodilation in SCD may be the result 
of an imbalance between ET-1-mediated vasoconstriction and apelin-mediated 
vasodilation.   
In human endothelial and vascular smooth muscle cells exposed to 
hypoxic conditions, apelin expression is significantly up-regulated, which may be 
a compensatory response to low oxygen levels in the tissue (Eyries et al., 2008).  
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Although the current study did not show a relationship between apelin levels 
alone and pain history or ratings, there are several limitations to the study design 
which might contribute to this negative finding.  The first being that apelin was 
sampled at a single time point from patients during disease steady state.  
Children who had a recent VOE or were taking current pain medications had 
been excluded from participating in the study.  It is possible that changes in 
apelin expression may be more pronounced during periods of vascular crisis 
when vasodilation has been shown to be significantly impaired in SCD patients 
(Belhassen et al., 2001).  Similarly, the imbalance between the apelin and 
endothelin systems found in this study may be more pronounced during a crisis.  
In addition, contributions of the apelin system in the current study may be 
underestimated based on our single sampling method since apelin has a short 
plasma half-life of less than 8 minutes (Japp et al., 2008).  
In the current study, the ratio of apelin to Big ET was positively correlated 
with a higher frequency of VOEs.  An increase in the ratio can result from 
increased apelin levels or decreased Big ET levels.  We have previously shown 
that lower plasma levels of Big ET were correlated with more recent VOEs 
(Schlenz et al., 2012).  The lower levels of Big ET may also result from an 
increased conversion of Big ET into the more active peptide, ET-1, by endothelin 
converting enzyme-1. 
 In the current study, apelin was found to decrease with age in children 
with SCD.  This decrease in plasma apelin levels with age parallels the decrease 
in circulating ET-1 with age in children with SCD (Lapoumeroulie et al., 
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2005).This suggests that there is developmental regulation of the vaso-regulatory 
systems in SCD.  These results are also consistent with animal studies showing 
a decrease in plasma apelin levels in aged rats (22 months) compared to young 
rats (3 months), which may suggest a developmental role for these mediators in 
the vascular system (Sauvant et al., 2014).  It should also be noted that the 
range of plasma level of apelin found in our study (0.87-10.74 ng/mL) is much 
higher than levels (0.0493 to 0.273 ng/mL) found in healthy adult volunteers in 
another study, which may be due to the decrease in apelin levels with age (Zhen 
et al., 2013).  In addition, ET-1-induced spontaneous nociceptive behaviors in 
rodents are age dependent (McKelvy et al., 2007).  Significantly greater ET-1-
induced nociceptive behaviors have been reported in younger animals compared 
to older animals.  Similarly, a priming effect with ET-1 has been characterized in 
young rodents in which increased ET-1 induced nociceptive behaviors are 
produced by a second exposure to ET-1 (McKelvy and Sweitzer, 2009).  This is 
important in certain disease states, such as sickle cell disease, in which there are 
repeated exposures to ET-1 with each subsequent VOE. 
Extrapolation of the current findings to larger patient populations is limited 
by the small sample size.  Although we attempted to separate the children by 
SCD genotype, we did not find any significant differences between the 
phenotypes for apelin or the two ratios. A larger sample size may reveal 
significant differences in plasma apelin levels and the ratios between the more 
severe genotypes and the more mild-moderate genotypes in regards to painful 
VOEs, since the different genotypes have been shown to influence the frequency 
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of VOEs and pain factors (Platt et al., 1991).  Another limitation of this study is 
the short half-lives of plasma apelin and ET-1 and Big ET, which are less than 8 
minutes, 1-2 minutes, and 23 minutes, respectively (Hemsen et al., 1995; Galie 
et al., 2004; Japp et al., 2008).   
This is the first study to explore the potential relationship between apelin 
and ET-1 in the pain associated with SCD.  The current results support the 
general postulate that children with SCD with higher numbers of VOEs may have 
a greater imbalance between the vasoconstrictive and pro-nociceptive systems 
and vasodilatory and anti-nociceptive systems.  Further studies in this area are 
needed to define and characterize the relationships between the apelin and 
endothelin systems in pain-associated with SCD.  If larger studies confirm that 
the balance between apelin and endothelin are important in SCD then 
modulating this target may be a unique therapeutic approach to treat and prevent 
VOEs. 
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Table 2.1.  Correlations for age, apelin, ratios, baseline and procedural pain, and recent VOEs. 
Note. The upper diagonal displays correlations with log-transformed ratio values whereas the lower diagonal displays 
correlations with untransformed ratio values.  † p<0.10, * p<0.05, ** p<0.01, *** p<0.001 
Variables 1 2 3 4 5 6 7 8 9 10 11 
1. Age - -.29* -.02 .07 -.29† -.07 -.42** -.35 -.30* -.49** .36* 
2. Apelin -.29* - .29* .51** -.14 -.03 .03 .03 -.01 .21 -.19 
3. Apelin/ET-1 
Ratio 
.05 .41** - .61** -.24 -.12 -.32* .05 -.11 .03 .16 
4. Apelin/Big ET 
Ratio 
.25† .43** .74** - -.29† -.30* -.23 -.07 -.22 .04 .23 
5. Child Report 
(Baseline Pain) 
-.29† -.14 -.25 -.22 - .53** .21 -.08 .09 -.06 -.14 
6. Caregiver 
Report 
(Baseline Pain) 
-.07 -.03 -.20 -.20 .53** - -.01 .28 .00 .19 -.01 
7. Obs. Distress 
(Baseline Distress) 
-.42** .03 -.24 -.20 .21 -.01 - .24 .24 .08 -.19 
8. Child Report 
(Procedural Pain) 
-.35* .03 -.10 -.23 -.08 .28 .24 - .27 .37* -.13 
9. Caregiver 
Report 
(Procedural Pain) 
-.30* -.01 -.14 -.35* .09 .00 .24 .27 - .18 -.21 
10. Obs. Distress 
(Procedural 
Distress) 
-
.49*** 
.21 .03 -.10 -.06 .19 .08 .37* .18 - .00 
11. RecentVOEs .36* -.19 .18 .27† -.14 -.01 -.19 -.13 -.21 .00 - 
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Figure 2.1 Negative correlation for the ratio between apelin and ET-1 and 
observational baseline pain ratings.  Higher ratings of observational baseline 
are significantly associated with lower ratios of apelin to ET-1 (N = 42). 
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Figure 2.2 Positive correlation for the ratio between apelin and Big ET and 
recent VOEs.  Higher ratio of apelin to Big ET are significantly associated with a 
higher number of recent VOEs (N = 42). 
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Figure 2.3 Relationship between disease severity phenotype and ratio 
between apelin and Big ET.  Trend for significantly higher ratio of apelin to Big 
ET in children with the more severe disease phenotype (N = 32) compared to 
children with the less severe phenotype (N = 11). 
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CHAPTER 3:   
 
Understanding the balance between the vasoconstrictor angiotensin 
II and the vasodilator apelin in the pain associated with sickle cell 
disease 
 37 
3.1 Introduction 
 This study sought to examine the involvement of another potent 
vasoconstrictor, Ang II in the complications associated with SCD.  This study also 
sought to understand the potential balance between Ang II and the vasodilator 
apelin in these complications since apelin has been shown to reverse Ang II 
induced vasoconstriction in isolated arteries (Zhong et al., 2007).  Angiotensin II 
is similar to ET-1 in that it is a potent vasoconstrictor with an important role in 
regulating vasomotor tone (Nguyen Dinh Cat and Touyz, 2011) and also has 
expression and receptors at multiple levels of the pain neuroaxis and may be 
involved in modulating pain hypersensitivity (Chakrabarty et al., 2008; Imboden 
et al., 2009; Chakrabarty et al., 2013).  Interestingly the role of angiotensin II as a 
pain modulator appears to be complex.  Both pronociceptive and antinociceptive 
effects of angiotensin II have been reported.  Anatomical site of administration, 
pain model, and species have all been shown to modify the functions of 
angiotensin II in the pain neuroaxis (Irvine and White, 1997; Georgieva and 
Georgiev, 1999; Marques-Lopes et al., 2009).   
 The goal of this study was to determine if the imbalance between ET-1-
induced vasoconstriction and apelin-induced vasodilation in children with SCD is 
specific for these two vasoactive peptides or more global and includes other 
vasoactive and potentially pain modulating endogenous peptides such as 
angiotensin II.  Both ET-1 and apelin are synthesized locally in the endothelial 
cells of the vasculature and released in a polarized fashion from endothelial to 
smooth muscle cells.  Hence, plasma levels of ET and apelin represent only a 
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small fraction of tissue levels at any given time.  In contrast, Ang II is a circulating 
peptide that is cleaved from angiotensinogen via multiple steps with a terminal 
cleavage to Ang II by angiotensin converting enzyme in the lungs.  Thus, plasma 
levels of Ang II are believed to be representative of levels acting on the 
vasculature.  In the current study, we postulate that plasma Ang II levels will 
display similar relationships to pain and symptoms as ET-1 because of the 
similar vasoactive and pronociceptive properties exhibited by these two 
endogenous peptides. 
3.2 Methods 
 The same plasma samples used for the previous chapter were used for 
this study.  The methods for the sample collection and more details on the 
primary outcome measures can be found in methods from Schlenz et al. (2012). 
 The enzyme immunoassay kit for Ang II was purchased from RayBiotech, Inc. 
(Cat#: EIA-ANGII-1, Norcross, GA).  The assay was performed in duplicate 
according to the manufacturer’s instructions.  A standard curve was plotted from 
the standards in the kit using Prism software (GraphPad Software, La Jolla, CA), 
which was used to extrapolate the Ang II concentration in each plasma sample.  
The percentage of absorbance in relation to the blank optical density was used in 
the determination of Ang II concentration in the samples.  Log-transformed 
values for Ang II concentrations were used since the untransformed values were 
highly skewed and variable.  The values for the ratio between Ang II and apelin 
were also log transformed for the same reason.  Five samples could not be 
analyzed; four samples contained Ang II concentrations that were below the level 
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of detection and one sample contained a concentration that was above the level 
of detection. 
 The primary outcomes explored for this study were baseline pain, 
procedural pain, ACS, recent VOE history, and SCD phenotype (disease 
severity).  The relationships between Ang II or the ratio between Ang II to apelin 
and baseline or procedural pain ratings or recent VOEs were analyzed using 
correlations.  A t-test was used to assess the relationship between Ang II or the 
ratio and ACS or SCD phenotype.  The relationship between Ang II or the ratio 
and age or gender was also explored using either correlation or a t-test.  The 
different procedural and baseline pain ratings are presented as log-transformed 
values because the original values exhibited a positive skew.  For the procedural 
pain ratings, since baseline pain ratings were associated with significantly greater 
procedural pain ratings, regression analysis was used to remove variance in 
procedural pain that could be attributed to baseline pain. 
3.3 Results 
3.3.1 Demographics  
 The untransformed Ang II levels ranged from 9.0-6,244 pg/mL (m = 408.9, 
SD = 1053.3).  There were no significant differences in Ang II plasma levels 
between males and females.  However, a significant correlation was found 
between Ang II and age (p = 0.0096, r = -0.438) with older children displaying 
lower levels of Ang II (Figure 3.1).  The ratio between Ang II and apelin did not 
reveal a difference for either gender or age. 
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3.3.2 Correlation with pain measures 
 No relationship was found between Ang II plasma concentration and the 
number of recent VOEs or observational baseline pain ratings (p = 0.582, r = -
0.097; p = 0.966,   r = 0.008, respectively).  A positive correlation was found 
between observational procedural pain ratings and Ang II where higher pain 
ratings are significantly associated with a higher level of plasma Ang II (p = 
0.0038, r = 0.497) (Figure 3.2).  No relationships were found between the ratio of 
Ang II to apelin and the number of recent VOEs or observational baseline pain 
ratings.  Higher observational procedural pain ratings were significantly 
correlated with a higher ratio of Ang II to apelin (p = 0.026, r = 0.387) (Figure 
3.3). 
3.3.3 Relationship to ACS 
 There was a trend for a difference between children with a history of ACS 
in the past 12 months and children without a history of ACS in relation to plasma 
Ang II levels.  Children who did not have a history of ACS tended to have higher 
levels of plasma Ang II levels (p = 0.074) (Figure 3.4). No differences were found 
between children with or without a history of ACS in relation to the ratio between 
Ang II and apelin. 
3.3.4 Relationship to disease severity 
 There was also a strong trend for a difference between severe (HbSS and 
HbSβ°) and mild-moderate (HbSC and HbSβ+) phenotypes with children who 
have the more mild-moderate phenotype having higher levels of Ang II (p = 
0.054) (Figure 3.5).  This difference was significant when the untransformed 
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values of Ang II were used in the analysis (data not shown).  No differences were 
found between the two disease severity phenotypes and the ratio between Ang II 
and apelin. 
3.3.5 Relationship of Ang II to apelin 
 Higher plasma Ang II levels were also significantly associated with higher 
levels of apelin (p = 0.012, r = 0.426) (Figure 3.6). 
3.4 Discussion 
This study examined plasma levels of angiotensin II in children with SCD 
with the goal of determining the potential involvement of the angiotensin system 
in pain and symptoms associated with SCD.  In addition, this study sought to 
determine how the balance between vasodilatory apelin and vasoconstrictive 
angiotensin II plasma levels impacts pain reports in children with SCD.  Similar to 
the endothelin and apelin systems, Ang II plasma levels also decrease with age, 
suggesting global developmental changes in vasoregulatory systems.  Future 
studies comparing vasoregulatory peptide plasma levels in children with and 
without SCD are needed to determine whether the developmental changes found 
in this study are specific for SCD.  Interestingly, a significant positive correlation 
between Ang II and procedural pain ratings was found, suggesting that Ang II 
may be involved in acute pain in children with SCD.   
 The goal of this study was to determine if the imbalance between 
vasoconstriction and vasodilation is specific for the endothelin system or whether 
the imbalance is global and might involve other vasoactive and pain modulating 
peptides such as angiotensin II.  These results suggest that the imbalance seen 
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between apelin and ET-1 in the previous chapter is specific for ET-1 rather than a 
general imbalance between apelin and vasoconstrictors.  Previous studies 
examining ET-1 in SCD have found increased plasma levels during VOEs 
(Graido-Gonzalez et al., 1998; Rybicki and Benjamin, 1998; Lapoumeroulie et al., 
2005).  Furthermore, elevated ET-1 plasma levels slowly decrease over the 
course of several weeks which temporally parallels the resolution of pain in 
children with SCD (Graido-Gonzalez et al., 1998).  Previous findings from our 
laboratory have found that plasma ET-1 levels are correlated with baseline pain 
in children with SCD.   The precursor Big ET levels are negatively correlated with 
higher frequency of recent VOEs in children with SCD, suggesting that 
decreased Big ET plasma levels may result from increased conversion to the 
active ET-1.  Similarly, ratios of apelin to ET-1 or Big ET have also been found to 
correlate with baseline pain and VOEs (Chapter 2).  In contrast to previous 
findings from our laboratory, no significant relationships were found for the ratio 
between Ang II and apelin and any of the SCD specific pain measures.  These 
findings suggest that the relationships identified with apelin and ET-1 or Big ET 
and SCD related pain measures are specific for the endothelin system. This is 
the first study that has demonstrated a potential relationship between angiotensin 
II and procedural pain in children with SCD, but not a relationship with SCD-
associated pain.    
 There is a growing preclinical literature suggesting that while Ang II plays 
an important role in the regulation of vasomotor tone by inducing 
vasoconstriction, it may also have a role in pain hypersensitivity through Ang II 
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receptor type 1 and 2 receptors (Chakrabarty et al., 2008; Imboden et al., 2009; 
Chakrabarty et al., 2013).  Depending on whether Ang II is injected peripherally 
or centrally, the particular pain model, or the species it can be either anti-
nociceptive or pro-nociceptive (Irvine and White, 1997; Georgieva and Georgiev, 
1999; Marques-Lopes et al., 2009).  It has been recently suggested that Ang II 
may act as a neuropeptide with multiple effects in the nervous system including 
modulation of pain transmission in the spinal cord (Nemoto et al., 2013).  For 
instance, intrathecal administration of Ang II produces nociceptive behaviors in 
rodents which can be blocked by both Ang II receptor inhibitors and opioids 
(Nemoto et al., 2013).  Furthermore, inhibition of Ang II in the rodent brain is anti-
nociceptive in acute pain models and this is thought to be mediated through the 
endogenous opioid system (Takai et al., 1996).  This suggests that the central 
actions of Ang II, possibly in the caudal ventrolateral medulla (Marques-Lopes et 
al., 2009), may have a role in enhancing acute pain (Takai et al., 1996).  In 
contrast, in spontaneously hypertensive rats, decreased pain sensitivity is 
reported, and this sensitivity can be attenuated with angiotensin I receptor 
antagonists (Irvine et al., 1995).  This suggests that peripheral, as opposed to 
central, angiotensin II may be anti-nociceptive in pathological states.  
Furthermore, peripheral angiotensin II has been postulated to increase the 
release of endogenous opioids to facilitate analgesia (Irvine and White, 1997).  In 
the current study, increased peripheral plasma levels were associated with 
increased acute procedural pain in children with SCD which is opposite of what 
would be predicted from preclinical studies.  One potential reason is that 
 44 
measurement of plasma Ang II does not rule out a potential central site of action 
of the peripherally circulating angiotensin II or centrally produced and released 
angiotensin II.  In fact, tissue levels of Ang II may be more important than 
circulating plasma levels in modulating both vascular reactivity and pain 
sensitivity (Schuijt et al., 2002). 
 Interestingly, especially in light of the vascular pathology in SCD, the 
vascular disease status may impact whether Ang II exerts anti-nociceptive or pro-
nociceptive activity.  Ang II has been postulated to play a role in pathological 
endothelial cell dysfunction and vascular hyper-reactivity, both of which may be 
involved in SCD (Schujt et al., 2002).  Two sub-phenotypes that have been 
identified in the complications associated with SCD: viscosity-vaso-occlusive and 
vasculopathy sub-phenotypes (Kato et al., 2009).  The viscosity-vaso-occlusive 
sub-phenotype is associated with acute painful VOEs and ACS while the 
vasculopathy or endothelial dysfunction sub-phenotype is associated with stroke, 
pulmonary hypertension, and chronic leg ulcers, which also has a pain 
component (van der Land et al., 2013).  So even though in this study Ang II was 
not found to be associated with the frequency of recent VOEs and baseline pain, 
which is thought to be related to vaso-occlusive pain, it may be possible that it is 
instead involved in the vasculopathy/endothelial dysfunction sub-phenotype.  
  Compared to an earlier study that found that Ang II levels in normal 
children range from 5-103 pg/mL, the children in this study display much higher 
levels of Ang II and a much larger variability (9-6,244 pg/mL) (Broughton Pipkin 
et al., 1981).  This difference could be attributed to the different ethnicities 
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studied or it could be due to the particular pathologies associated with SCD.  It 
has been noted that in transgenic sickle cell mice, removal of the vasodilatory 
component unmasks an upregulation of vasoconstrictive systems, and the high 
levels of Ang II found in this study may lend to the possibility that Ang II could be 
one of these systems (Nath et al., 2000).  A consequence of the imbalance in 
vasoconstrictors and vasodilators is vascular instability, which may contribute to 
a state of vasculopathy and endothelial dysfunction (Hebbel, 2014).  One 
possible candidate for contributing to the state of vasculopathy and endothelial 
dysfunction is Ang II since it has been implicated in contributing to endothelial 
dysfunction in other pathologies (Taguchi et al., 2011).  This study also confirms 
our finding of a decrease in Ang II levels with age.    
 As with any clinical study, there are several limitations in the current study.  
The first limitation is the small sample size, which makes extrapolation of the 
current findings to larger patient populations limited.  An attempt to separate the 
children by SCD genotype resulting in even small sample numbers did not show 
any significant differences between the phenotypes for Ang II.  Another limitation 
of this study is the measurement of Ang II in blood plasma, which is only 
capturing circulating levels as opposed to actual tissue levels.  This is further 
confounded by the short half-life of Ang II.  In the rat, the half-life of Ang II is 
estimated to be around 16 seconds in the plasma (Al-Merani et al., 1978), and 
according to the manufacturer of the Ang II enzyme immunoassay kit, the half-life 
of Ang II in human plasma is approximately 30 seconds.  The time between 
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blood collection and the placement on ice varied for each participant, which may 
explain the large variation in the Ang II levels. 
 One of the most interesting findings is that while we have previously 
shown a correlation between the endothelin (and apelin) systems and SCD-
related pain but not procedural pain, the current study suggests that Ang II is not 
involved in SCD-related pain but is involved in acute pain.  This suggests that 
future clinical studies should explore the utility of endothelin antagonists in SCD-
related pain conditions and Ang II inhibitors on acute pain in children with SCD.  
This study also highlights the importance of discriminating the causes of pain in 
children with SCD as the different forms of pain may be responsive to varied 
pharmacotherapy approaches.  
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Figure 3.1 Negative correlation between plasma Ang II levels and age.  
Lower plasma levels of Ang II are significantly correlated with older children (N = 
34). 
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Figure 3.2 Positive correlation between Ang II plasma levels and 
observational procedural pain ratings  Higher plasma levels of Ang II were 
significantly correlated to higher ratings of procedural pain in children with SCD 
(N = 32) 
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Figure 3.3 Positive correlation between ratio of Ang II to apelin and 
observational procedural pain ratings.  A higher ratio of Ang II to apelin in the 
plasma was significantly correlated with higher ratings of observational 
procedural pain (N = 33). 
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Figure 3.4 Plasma levels of Ang II and history of ACS.  Trend for higher levels 
of plasma Ang II in children without a history of ACS compared to children with a 
history of ACS in the past 12 months. 
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Figure 3.5 Plasma levels of Ang II and disease severity.  Trend for higher 
levels of plasma Ang II levels in children with a less severe phenotype of SCD 
(children with the HbSC and HbS+ genotypes) compared to children with the 
more severe phenotype (HbSS and Hb°). 
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Figure 3.6 Positive correlation between Ang II and apelin.  Higher plasma 
levels of Ang II were significantly correlated with higher plasma levels of apelin 
(N = 34).
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CHAPTER 4: 
 
Endothelin-1-induced priming to capsaicin in young animals1 
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4.1 Introduction 
Vaso-occlusive episodes (VOEs) accompanied by extreme pain is a 
hallmark feature of sickle cell disease (SCD).  The vasoactive peptide endothelin-
1 (ET-1) has been found to be elevated in SCD patients during an acute VOE 
(Graido-Gonzalez et al., 1998).  Endothelin-1 is a 21 amino acid peptide known 
to be a potent vasoconstrictor which causes acute pain and sensitization to 
mechanical and other noxious stimulation when injected into the human forearm 
(Ferreira et al., 1989; Dahlof et al., 1990; Hans et al., 2007).  When ET-1 is 
injected into the rat hindpaw (Gokin et al., 2001) or directly onto the sciatic nerve 
(Davar et al., 1998), it induces spontaneous nociceptive behaviors.  Repeated 
administration of ET-1 onto the sciatic nerve of adult male rats causes 
desensitization as evident by a reduction in nociceptive behaviors (Fareed et al., 
2000).  Previous results from our lab have shown that prior exposure to ET-1 
alters behavioral responses to subsequent exposure to ET-1 at the same location 
in a sex dependent manner with sensitization in males and desensitization in 
females (McKelvy and Sweitzer, 2009).  However, when the second 
administration of ET-1 was in the contralateral hindpaw a sensitization was 
observed in both males and females.   
To determine whether the contralateral increase in ET-1-induced 
nociception is a result of central sensitization, this study applied capsaicin to the 
contralateral hindpaw and examined secondary mechanical hyperalgesia, which 
is when a noxious mechanical stimulus becomes even more noxious, and 
neuronal activation in the dorsal horn of the spinal cord using c-fos.  This study 
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tested the hypothesis that a priming dose of ET-1 produces central sensitization, 
which will cause an increase capsaicin-induced secondary mechanical 
hyperalgesia in the contralateral hindpaw and c-Fos expression in the spinal 
cord. 
4.2 Methods 
4.2.1 Animals 
All experimental protocols were approved by the Institutional Animal Care 
and Use Committee at the University of South Carolina.  Efforts were made to 
limit the amount of distress and the number of animals used.  Male and female 
Sprague-Dawley (Charles River Laboratories, MA) pups were housed with dams 
on a 12 hour light/dark cycle with food and water available ad libitum.  Each litter 
was culled at 10-12 pups. 
4.2.2 ET-1 and capsaicin administration and behavioral analysis 
 Sterile saline or ET-1 (Enzo Life Sciences, Farmingdale, NY, USA) 
dissolved in deionized water was administered (5.25 pmol) in 10 µL (1.31 ng/µL) 
subcutaneously using an insulin syringe into the left plantar hindpaw on postnatal 
day 7 (P7).  Animals were videotaped, and the number of spontaneous paw 
flinches was counted.  On postnatal day 11 (P11), capsaicin cream (0.1% 
Capzaisin-HP, Chattem, Inc, Chattanooga, TN, USA) or control lotion (Johnson & 
Johnson Baby Lotion) was applied topically to the dorsum of the right hindpaw.  
There were four treatment groups for both sexes (n=5-6 for each group and sex): 
saline (P7)+control (P11), saline (P7)+capsaicin (P11), ET-1 (P7)+control (P11), 
and ET-1 (P7)+capsaicin (P11).  Before application of capsaicin, the baseline 
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paw withdrawal threshold was measured in the plantar right hindpaw using 
sequential von Frey filaments ranging from 0.04 g to 1.4 g.  Each filament was 
applied a total of five times and the first filament that elicited a sustained 
response was considered the paw withdrawal threshold.  This method was used 
at 20, 40, 60, and 120 minute time points following capsaicin application.   
4.2.3 Fos immunohistochemistry 
 Two hours post-capsaicin on P11, all animals were deeply anesthetized 
with isoflurane then transcardially perfused with cold phosphate buffered saline 
(PBS) and 4% paraformaldehyde followed by isolation of the vertebral columns.  
Spinal cords were isolated and equilibrated in a cyroprotecting solution (30% 
sucrose in PBS).  Spinal cords were mounted in Tissue-Tek O.C.T. Compound 
(Sakura Finetek, Torrance, CA, USA) and sliced into serial 40 µm transverse 
sections.  Sections were stored in anti-freeze solution (ethylene glycol and 
sucrose in PBS) at -20°C until processed for immunofluorescence or 
immunoperoxidase.  Free-floating sections were blocked in normal horse serum 
before being incubated with polyclonal rabbit anti-c-Fos (EMD Biosciences, 
Billerica, MA, USA, 1:5000) overnight at 4°C.  Following a wash, the tissue 
sections were then incubated with donkey anti-rabbit Alexa Flor 594 (Invitrogen, 
Carlsbad, CA, USA, 1:200) or biotinylated donkey anti-rabbit (Jackson 
Immunoresearch, West Grove, PA, USA, 1:1000) for 1.5 hours at room 
temperature then washed, slide mounted, and coverslipped using Vectashield 
(Vector Laboratories, Burlingame, CA, USA).  For immunoperoxidase, sections 
were incubated in HRP-streptavidin (Jackson Immunoresearch, 1:1600) for 1 
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hour at room temperature followed by exposure to DAB and mounting on gelatin 
coated slides.  The total number of c-Fos positive cells was counted in the L3-L5 
dorsal horns by an experimenter blinded to treatment.  Due to the diffuse 
expression of c-Fos expression across the dorsal horn in spinal cords from 
relatively immature animals, the expression was counted in both superficial and 
deeper dorsal horns.    
4.2.4 Data Analysis 
 One-way ANOVA was used for comparing the number of ET-1 induced 
paw flinching on postnatal day 7 (treatment and sex).  Two-way ANOVA was 
used for comparing time versus treatment between sexes in the capsaicin induce 
mechanical hyperalgesia study.  One-way ANOVA was used for comparing the 
number of c-Fos positive neurons (treatment and sex).  The conservative 
Bonferroni post-test was used for all analysis and a p-value < 0.05 was 
considered significant.  All statistical analysis was done with GraphPad Prism 5 
(GraphPad Software, Inc, San Diego, CA). 
4.3 Results 
4.3.1 Behavioral Analysis 
 Administration of ET-1on P7 elicited a significantly greater number of paw 
flinches compared to saline administration in both male and female rats (p<0.05; 
Fig. 4.1 A).  No differences between sexes was observed on P7 (ET-1 female vs. 
ET-1 male, p>0.05; saline female vs. saline male, p>0.05).   
Administration of capsaicin to the contralateral dorsal hind paw on P11, 
produced secondary mechanical allodynia, which is defined as a non-noxious 
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stimuli becoming noxious at a site beyond the area of injury, in the plantar hind 
paw (Fig 4.1 B,C).  In saline control animals, the duration of secondary allodynia 
was sex-dependent (Fig 4.1 B,C).  In control males not previously exposed to 
ET-1, topical capsaicin produced secondary mechanical allodynia at all time 
points examined including 120 minutes post-capsaicin (Fig. 4.1 B).  In control 
females not previously exposed to ET-1, topical capsaicin produced secondary 
mechanical allodynia of a short duration (Fig 4.1 C).  Secondary mechanical 
allodynia was only observed at 20 minutes after capsaicin administration.  At 40 
minutes post-capsaicin administration control saline females had significantly 
higher paw withdrawal thresholds compared to capsaicin-treated control saline 
males (p<0.05).  This suggests sex-dependent capsaicin-induced secondary 
allodynia in neonatal rats.   
Priming with ET-1on P7, did not alter the magnitude or duration of 
capsaicin-induced secondary mechanical hyperalgesia in males.  There were no 
significant differences found between the primed and unprimed males at any of 
the time points (Fig. 4.1 B).  In contrast, priming with ET-1 on P7, sensitized 
females to capsaicin induced secondary mechanical hyperalgesia (p<0.01 versus 
control across the time course) demonstrated by a significant reduction in paw 
withdrawal threshold across the entire 120 minutes (Fig 4.1 C).  Interestingly, 
females primed with ET-1 on P7 had greater capsaicin induced secondary 
mechanical hyperalgesia as measured by a lower paw withdrawal threshold 
when compared to males primed with ET-1 on P7 (p<0.05 across time).  
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Administration of vehicle cream did not alter paw withdrawal thresholds across 
the time course in primed and unprimed males and females (data not shown). 
4.3.2 Fos expression 
 ET-1 priming significantly increased capsaicin-induced c-Fos expression 
in both males and females (p<0.001) compared to the unprimed animals and 
compared to control (Fig. 4.2 A-C).  C-Fos expressing neurons were found in 
both superficial and deeper dorsal horn lamina (see Fig. 4.2 A).  Animals that 
were primed with ET-1 and received capsaicin on P11 had significant c-Fos 
expression in the right dorsal horn (Fig. 4.2 A-C) compared to the animals who 
received saline on P7 and capsaicin on P11.  Primed males treated with 
capsaicin had significantly greater c-Fos compared to primed females treated 
with capsaicin (p<0.001).  Interestingly, priming also increased c-Fos expression 
on the contralateral paw in males but not females (data not shown).   
4.4 Discussion 
 The nociceptive response to capsaicin was sex dependent with males 
developing a longer lasting capsaicin induced secondary mechanical 
hyperalgesia compared to females.  Priming with ET-1 on P7 sensitized females 
to capsaicin induced secondary mechanical hyperalgesia.  These results also 
demonstrate that capsaicin causes a greater increase in Fos expression in the 
dorsal horns of ET-1 primed animals compared to ET-1 naïve animals, with a 
larger induction in males as compared to females.  The results of this study 
provide more evidence for the hypothesis that pain early in life can alter the 
response to subsequent noxious stimuli and this alteration may be sex 
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dependent.  The neonatal period has been found to be a critical period for injury-
induced changes to nociceptive processing, and these changes affect 
subsequent responses to noxious stimuli (Fitzgerald, 2005).  In children with 
sickle cell disease, the risk of experiencing a painful crisis occurs in the first year 
of life and increases thereafter (Gill et al., 1995). 
 In female rats, capsaicin induced a short duration secondary mechanical 
hyperalgesia on postnatal day 11.  Priming with ET-1 on postnatal day 7 
increased the duration of capsaicin-induced secondary mechanical hyperalgesia.  
In addition, priming with ET-1 led to greater capsaicin induced secondary 
mechanical hyperalgesia in females as compared to males.  These results 
correspond with research that has reported sexually dimorphic differences in 
nociceptive thresholds in adulthood after neonatal injury (LaPrairie and Murphy, 
2007).  They also relate to clinical research that has shown that female sickle cell 
anemia patients have a higher incidence of painful crisis compared to male sickle 
cell anemia patients (Gill et al., 1995). 
 The significantly higher Fos expression seen in the ET-1 pre-treated 
animals suggests that the priming effect of ET-1 may be centrally mediated at the 
level of the spinal cord.  However, it cannot be ruled out that ET-1 priming may 
also have supraspinal effects on descending modulation, such as enhancing 
facilitation of nociceptive inputs or reducing descending inhibition (Porreca et al., 
2002; Hohmann et al., 2005).  It is possible that similar to inflammatory pain, ET-
1-induced nociception may cause a shift in the balance from inhibition to 
facilitation in the capsaicin treated animals (Ren and Dubner, 2002).  In contrast 
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to prior reports showing no Fos expression in the contralateral dorsal horns of 
adult rats after treating with capsaicin in the neonatal period, we show Fos 
expression in the contralateral dorsal horns (Hohmann et al., 2005).  However, 
this difference may be explained by the fact that in the prior report, Fos 
expression was measured in adulthood as opposed to the neonatal period.  At 
this time it is not exactly clear what the functional significance is of the activation 
of contralateral neurons.  One possible explanation is that the activation of these 
contralateral neurons could be due to the activation of polysynaptic pathways 
involving neuronal connections to the brainstem (Kaczmarek, 2002).  The 
observation of Fos expression in the deeper dorsal horns may be explained by 
an increase in the response of wide dynamic range and low-threshold neurons, 
which has been shown to happen after neonatal chronic inflammation (Ruda et 
al., 2000; Peng et al., 2003). 
 The repetitive nociceptive pain experienced by sickle cell patients early in 
life may contribute to the development of chronic pain experienced by some 
patients later in life (Smith and Scherer, 2010).  Because SCD patients may 
experience repeated painful crises throughout the infant and childhood periods, it 
is important to find better ways to effectively relieve pain during these critical 
periods. 
 Together, the results of this study suggest that pain in early life may alter 
future responses to painful stimuli at both the behavioral and neuronal level and 
the response at the behavioral level is sexually dimorphic.  These results also 
  
62 
suggest that, at least in part, the contralateral sensitizing effect is mediated 
centrally in the spinal cord. 
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Figure 4.1 ET-1-induced spontaneous behavior and capsaicin-induced 
secondary allodynia. Sex-dependent ET-1 priming on capsaicin induced 
secondary allodynia and spinal cord c-fos expression.  (A)  Intraplantar ET-1 
administration increased the total number of spontaneous paw flinches on 
postnatal day 7 (*p<0.05 ET-1 vs saline same sex).  (B) In males, priming had no 
effect on capsaicin induced secondary allodynia in the contralateral hind paw 
(*p<0.05 vs time 0 baseline, #p<0.05 vs primed animals).  (C)   In females, 
priming prolongs capsaicin-induced secondary allodynia in the contralateral hind 
paw (*p<0.05 vs baseline, #p<0.05 vs primed animals, αp<0.05 vs. males).    
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Figure 4.2 ET-1 priming effect on capsaicin-induced c-Fos expression.  (A) 
Representative micrographs of c-Fos staining in the right dorsal horn of the 
spinal cord. (A1) Ipsilateral and contralateral dorsal horn from male ET-1 + 
Capsaicin treatment.  Large arrows point to deep dorsal horn c-Fos positive 
neurons.  Small arrows point to superficial dorsal horn c-Fos positive neurons.  
Box indicates area that is shown in higher magnification in figure A2.  (A3) 
Ipsilateral dorsal horn from female ET-1 + Capsaicin treatment.  Scale bar 
represents 500 µm in A1 and 50 µm in A2 and 3.  (B) In females, priming 
increases capsaicin-induced c-Fos in the dorsal horn (***p<0.001 vs. control).  
(C) In males, priming increases capsaicin-induced c-Fos in the dorsal horn 
(***p<0.001 vs. control; αααp<0.001 vs. females).   
 1Smith, T and Sweitzer, S.M. Endothelin-1 induced desensitization in primary afferent 
neurons. Submitted in part to Neuroscience Letters. 06/16/2014 
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CHAPTER 5: 
 
Examining the Endothelin and Apelin Systems in Animal and in vitro 
Model of Acute VOEs1 
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5.1 Introduction 
Our lab has previously used an acute administration of ET-1 in rats to 
model an acute VOE associated with a sickle cell crisis.  In this model, repeated 
administration of ET-1 results in a sex-dependent priming effect.  In males, ET-1 
exposure produces sensitization to a second exposure to ET-1 and this ET-1-
induced sensitization is associated with down-regulation of the ETB receptor 
(McKelvy and Sweitzer, 2009).  The ETB receptor produces vasodilation in the 
vasculature and release of endogenous opioids from keratinocytes in the skin, 
suggesting that ETB receptor activation has analgesic effects in the skin 
(Mazzocchi et al., 1998; Khodorova et al., 2003).  In contrast, in females, prior 
exposure to ET-1 produces desensitization to a second exposure to ET-1 and 
causes an up-regulation of the ETB receptor (McKelvy and Sweitzer, 2009).  
Furthermore, in the previous chapter we showed that priming with ET-1 
enhances capsaicin-induced secondary hyperalgesia in both males and females 
and that this is accompanied by enhanced c-Fos activation in dorsal horn 
neurons.   
 The first goal of this phase of the project was to determine if ET-1-induced 
sensitization is also mediated at the primary afferent neuron level.  To examine 
this, primary DRG cell cultures were kept in culture for four days to mimic the 
timeline (P7-P11) in our in vivo model and exposed to ET-1 to simulate an acute 
VOE.  Calcium imaging was used to measure neuronal activity in these DRG 
cultures after exposure to ET-1.  The second step of this phase of the project, 
builds upon our previous clinical findings that the ratio between apelin and 
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endothelin correlates with VOEs and baseline pain in children with SCD.  This 
phase sought to examine the role of the apelin system in our rodent and in vitro 
model of acute VOEs.  These studies entailed western analysis of APJ receptor 
expression in the pain pathway, using cultured DRG cells to examine the apelin-
ET-1 functional intersection in afferent neurons, and skin release assays to 
determine the impact of ET-1 on apelin release. 
5.2 Methods 
5.2.1 Cell Culture 
 Dorsal root ganglia (DRG) from adult male rats were dissected and 
collected in ice cold Tyrode buffer (132 mM NaCl, 4.8 mM KCl, 1 mM MgCl2, 1 
mM CaCl2, 5 mM dextrose, 5 mM HEPES).  DRGs were digested using a 
solution of dispase (1 mg/mL, Gibco 171050-041) and collagenase (2 mg/mL, 
Roche 1088831) in Tyrode buffer and incubation in a shaking water bath at 37°C 
for 45 minutes.  Following digestion, the DRGs were triturated with a fire polished 
Pasteur pipet followed by separation using an OptiPrep (Sigma D1556) gradient.  
Cells were centrifuged at 1900 rpm for 20 minutes then the bottom layer was 
isolated and the cells were counted.   
The DRG cells (both neurons and support cells) were seeded in 96 well 
black clear bottom plates (Costar, Corning Inc.) coated with poly-D-lysine at a 
density of approximately 60,000-80,000 cells per well (day 0).  Cells were 
maintained in Minimum Essential Medium Eagle media (Sigma Aldrich M0643) 
(supplemented with 20% glucose, 10% FBS (Invitrogen 16000-036), 1% 
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penicillin-streptomycin solution (Invitrogen 15070-063), and 10 μg/ml of NGF 
(Millipore 01-125).   
5.2.2 Calcium imaging for ET-1 experiment 
 Cells were maintained in culture for 4 days and on the 5th day, calcium 
imaging was performed.  On day 0 (the day of culture), cells were either treated 
with 1.1 nmole of ET-1 (22 μM, Enzo Life Sciences) or vehicle (sterilized 
deionized water).  On day 4, cells were first washed with either Ca2+-containing 
NaCl-based extracellular (EC) buffer (130 mM NaCl, 2.5 mM KCl, 1mM MgCl2, 4 
mM CaCl2, 10 mM HEPES, 5mM glucose) with 2.5 mM probenecid (Molecular 
Probes P36400) or Ca2+-free NaCl-based EC buffer then incubated with Fluo-
4AM solution (1 μM, Molecular Probes, Invitrogen F14201) containing pluronic 
acid at 37°C for 1 hour.  After incubation with the dye solution, cells were washed 
twice with the appropriate NaCl-based EC buffer, then 190 μl of the appropriate 
buffer was added to each well.  After incubation at 37°C for 1 hour, the plate was 
loaded into the BioTek Synergy 2 plate reader and the BioTek Gen5™ Data 
Analysis Software was used to perform reader control.  After a 5 minute delay, 
the cells were baselined every 5 seconds for 30 seconds.  Following the baseline 
measures, either 10 μL of ET-1 (0.55μM) or 10 μL of vehicle (sterile filtered 
deionized water) was injected into the appropriate wells by hand.  The change in 
fluorescence was then measured every 3 seconds for 3 minutes.  Fluorescence 
was excited at 485 nm and emission was measured at 528 nm.  Temperature 
was maintained at 37°C.  A total of 6 wells were measured for each treatment 
group. 
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5.2.3 Drug treatment and Ca2+ Imaging for ET-1 time course 
 The cells were treated with either ET-1 (2.2 µM, Alexis Biochemicals) or 
vehicle for a period of 4 days.  On day 0, one set of cells was treated with ET-1 
and the others treated with vehicle.  On day 1, the culture media was changed 
and a different set of cells was treated with ET-1 and the others treated with 
vehicle.  This was repeated on days 2 and 3 with a different set of cells being 
pre-treated once with ET-1 during the treatment period.  There were a total of 6 
wells for each treatment group. 
 On day 4, calcium imaging was performed.  Cells were loaded with the 
dye solution as mentioned previously.  The plate reader was programmed to 
have a 5 minute delay, after which, baseline measurements were taken every 5 
seconds for 30 seconds for the first set of wells.  ET-1 (10 μl, either 5.5 μM or 
0.55 μM) or vehicle (10 μl) was added to the appropriate wells, then readings 
were made continuously every 3 seconds for 3 minutes.   
5.2.4 Calcium imaging for capsaicin experiment 
 The cells were treated with either vehicle (sterile filtered deionized water) 
or 1.1 nmole of ET-1 (22 μM, American Peptide, Sunnyvale, CA on day 0 (the 
day of cell culture).  On day 4, calcium imaging was performed.  Following the 
baseline measures, either 10 μL of capsaicin (1μM) or 10 μL of vehicle (DMSO in 
NaCl-based EC buffer) was added to the appropriate wells (5 wells/treatment 
group) and the change in fluorescence measured every 3 seconds for 5 minutes.  
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5.2.5 Western blot analysis 
 On postnatal day 7, rats received either an intraplantar injection of ET-1 
(3.3 nmol American Peptide) or saline.  Postnatal day 11 rats were given an 
overdose of isoflurane and the hindpaw skin and spinal cords were collected and 
frozen at -80°C until ready for analysis.  The tissues were homogenized and a 
bicinchoninic acid assay (BCA assay) was used to determine protein 
concentration for each sample.  For Western blot analysis, 33 µg of protein was 
loaded for each sample onto a 4-15% Tris HCl Criterion gel (BioRad).  The 
separated proteins were then transferred to a PVDF membrane.  The membrane 
was blocked in 5% milk for one hour at room temperature, then incubated with 
the rabbit anti-APJ receptor antibody ([1:1000], Santa Cruz Biotechnology) 
overnight at 4°C.  Following a few washes, the membrane was incubated in 
donkey anti-rabbit secondary antibody ([1:4000], Jackson Immunoresearch 
Laboratories) for one hour at room temperature.  Protein expression was 
visualized using enhanced chemiluminescence (ECL).  Beta-actin was used as a 
loading control and the ratio of APJ receptor expression to beta-actin expression 
was used in the analysis. 
5.2.6 Apelin-ET-1 calcium imaging 
 Cells were cultured as previously mentioned from adult male rats.  Two 
paradigms were explored for this experiment.  In the first paradigm, the cells 
were primed with either 1.1 nmole of ET-1 (5.5 µM, American Peptide), a 
combination of ET-1 and 2 nmole of pyroglutamylated apelin-13 (10.1 μM, 
American Peptide), apelin alone, or vehicle on the day of culture.  On day 4, 
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calcium imaging was performed and cells were either challenged with 0.55 µM of 
ET-1 or vehicle.  In the second paradigm, the cells were primed with either 1.1 
nmole of ET-1 or vehicle on the day of culture.  On day 4, calcium imaging was 
performed and cells were challenged with either 0.55 µM of ET-1, a combination 
of ET-1 and 5.5 µM of apelin, or apelin alone.  Following baseline measures, the 
peptides were added to the appropriate wells (5 wells/treatment group) and the 
change in fluorescence was measured every 3 seconds for 3 minutes. 
5.2.7 Skin release assay and ELISA  
 On postnatal day 11, hindpaw skin was collected from both male and 
female rats and maintained in artificial interstitial fluid (aIF).  Skin release 
fractions were collected before incubation with an ETB receptor agonist (IRL-
1620, American Peptide), during incubation with agonist, and after incubation 
with agonist.  The skin release fractions were then analyzed for apelin (Phoenix 
Pharmaceuticals) using EIA. 
5.2.8 Data analysis 
 GraphPad Prism Software was used for all statistical analysis.  For 
comparison between treatment groups for all of the Ca2+ imaging experiments, 
one-way ANOVA followed by a Bonferroni post hoc test was employed. One-way 
ANOVA followed by a Bonferroni post-hoc test was also employed for all of the 
Western blot results.  For the skin release assay, a two-way ANOVA was used to 
determine the effects of both sex and treatment with the ETB receptor agonist.  
P<0.05 was considered to be statistically significant.   
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5.3 Results 
5.3.1 Effect of ET-1 on [Ca2+]i in afferent neurons 
 To determine whether behavioral desensitization is driven by afferent 
neuron desensitization, an in vitro model using cultured DRG neurons and 
calcium imaging was developed.  The experimental design was to apply ET-1 on 
day 0 of culture and then measure ET-1 stimulated Ca2+ influx four days later.  
On day 4 in culture, application of 0.55 μM of ET-1 onto  naïve cells significantly 
increased intracellular Ca2+ compared to vehicle treated cells (p<0.001) (Figure 
5.1 A).  However, priming with 22 μM of ET-1 on day 0 followed by a challenge 
with 0.55 μM of ET-1 on day 4 did not produce a significant influx of Ca2+ into the 
cultured afferent neurons (Figure 5.1 A).  The ET-1-induced increase in 
intracellular Ca2+ due to ET-1 is dependent on extracellular Ca2+, as removal of 
Ca2+ from the extracellular buffer prevents ET-1-induced Ca2+ transients (Figure 
5.1 A inset).  Similarly, a reduction in area under the curve (AUC) (Fig 5.1 B) and 
maximum peak height (Fig 5.1 C) is seen in ET-1 primed cells compared to 
unprimed cells exposed to ET-1 for the first time at the time of imaging (Fig 5.1 
B).  The time to the calcium peak is similar between treatments with a trend to a 
more rapid peak in cells exposed to ET-1 compared to vehicle (Fig 5.1 D). 
5.3.2 Time course of priming effect of ET-1 
 To examine the time course of the priming effect, cells were primed with 4, 
3, 2, or 1 day before the ET-1 challenge dose.  Application of low dose (0.55 µM, 
Fig 5-2 A) or high dose (5.5 µM, Fig 5.2 B) of ET-1 produced a statistically 
significant rise in [Ca2+]i.   Priming of the cells with 2.2 µM of ET-1 on Day 1, 2, or 
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3 of culture produced a time-dependent blockade of the ET-1 stimulated rise in 
[Ca2+]i when a low challenge dose of ET-1 was used (Fig 5.2 A, C).  In contrast, 
priming on any day suppressed calcium transients when a high challenge dose of 
ET-1 was used (Fig 5.2 B, C).  Measurement of the maximum peak height (Fig 
5.2 E) showed similar time dependent priming with low but not high dose ET-1 as 
the area under the curve measurements (Fig 5.2 C).  The time to peak was 
similar in all treatments using a low dose ET-1 challenge (Fig 5.2 D).  In contrast, 
the time to peak was delayed by priming on days 1 and 3 when a high dose of 
ET-1 was used to challenge (Fig 5.2 D).  This data suggests that both the day of 
priming and the challenge dose of ET-1 have a significant impact on ET-1 
induced desensitization in primary afferent neurons. 
 5.3.3 Effect of ET-1 priming on capsaicin-induced increase in [Ca2+]i 
 As we have previously demonstrated (Chapter Four) in this thesis, prior 
exposure to ET-1 can modify subsequent behavioral nociceptive responses to 
capsaicin.  The purpose of this experiment was to determine whether that effect 
of ET-1 priming on capsaicin responses might be mediated at the level of the 
afferent neuron.  Treatment of cells with capsaicin on day 4 causes a significant 
increase in [Ca2+]i  compared to cells treated with vehicle on day 4 (p<0.001) 
(Figure 5.3).  Priming with ET-1 on day 0 then challenging with capsaicin causes 
significantly lower increase in [Ca2+]i compared to cells treated with vehicle on 
day 0 then given capsaicin on day 4 (p<0.001) (Figure 5.3). 
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5.3.4 APJ receptor expression in rodent hindpaw skin and spinal cord 
 No significant differences in APJ receptor expression were found in the 
hindpaw skin between the normal, saline, or ET-1 treated P11 male rats; 
however, there was a trend for a decrease in APJ receptor expression in ET-1 
treated rats (Figure 5.4 A).  However in the spinal cord of male rats given ET-1, 
there was a significant increase in APJ receptor expression compared to male 
rats given saline of P7 (p<0.05) (Figure 5.4 B).  No significant differences in APJ 
receptor expression in the spinal cord were found between female rats given ET-
1 on P7 and female rats given saline on P7.  This data suggests that APJ may 
play a sex dependent role in ET-1 induced priming. 
5.3.5 Apelin-ET-1 interactions in afferent neurons 
 Cultured DRG neurons were used to examine whether apelin can modify 
ET-1-induced Ca2+ transients in afferent neurons.  For the first paradigm, there 
were significantly greater increases in [Ca2+]i in cells primed with vehicle or apelin 
alone then challenged with 0.55 µM of ET-1 compared to ET-1 primed cells 
challenged with ET-1 (Figure 5.5 A, C) and all vehicle challenged groups (Figure 
5.5 B, C).  There were no significant changes in fluorescence in vehicle 
challenged groups as expected (Figure 5.5 B, C).  The time to peak was 
significantly greater in apelin primed cells challenged with ET-1 compared to 
unprimed and apelin primed cells challenged with vehicle (Figure 5.5 D).  The 
maximum peak height was significantly greater in ET-1 challenged unprimed 
cells compared to all other treatment groups except unprimed vehicle challenged 
and apelin primed ET-1 challenged cells (Figure 5.5 E). 
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 For the second paradigm, a challenge with 0.55 µM of ET-1or a 
combination of ET-1 and 2 nmoles of apelin in unprimed cells causes the 
greatest change in fluorescence compared to cells challenged with vehicle or 
apelin (Figure 5.6 A, C) and all ET-1 primed cells (Figure 5.6 B, C).  There was a 
significantly greater AUC for ET-1 primed cells challenged with a combination of 
ET-1 and apelin compared to ET-1 primed cells that were challenged with ET-1 
(Figure 5.6 C).  Apelin causes a slower time to calcium peak in both primed and 
unprimed cells compared to cells challenged with vehicle or ET-1 (Figure 5.6 D).  
Unprimed cells challenged with either ET-1 alone or a combination of ET-1 and 
apelin had significantly greater maximum peak height compared to all other 
treatment groups except unprimed cells challenged with vehicle (Figure 5.6 E). 
5.3.6 Skin release assay  
 The hindpaw skin isolated from male rats showed a significant decrease in 
release of apelin when the ETB receptor agonist, IRL-1620, was applied 
compared to the time before and after the agonist was applied (p<0.05) (Figure 
5.7).  This decrease in apelin release was also significantly lower than the apelin 
levels measured in the hindpaw skin from female rats when the agonist was 
applied.  No differences were found in apelin release between the periods before, 
during, and after application of the agonist for female rats.  
5.4 Discussion 
 In this study, we examined the endothelin system in an in vitro model 
correlate of our animal model of localized acute VOEs as well as the apelin 
system in our animal model.  We found that in our in vitro model in primary 
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afferent neurons from DRGs, ET-1 causes a large influx of Ca2+ in naïve cells, 
but a “desensitized” response in ET-1 primed cells.  The ET-1 priming effect is 
dependent upon the timing of the priming dose as well as on the dose of the ET-
1 challenge. Similarly, ET-1 priming desensitizes primary afferent neurons to 
subsequent challenge with capsaicin.   
 To begin to understand whether the apelin system may be involved in ET-
1-induced changes in nociception and afferent neuron activation we examined 
expression of the apelin APJ receptor in our rodent model.  We found sex-
dependent changes in APJ expression in the spinal cord; however in the skin of 
male animals exposed to a priming dose of ET-1, no significant changes were 
seen.  At the level of the DRG, apelin did not completely attenuate or potentiate 
ET-1 induced calcium transients in primed or unprimed cells suggesting that 
apelin does not have a direct effect on afferent neurons in modulating 
nociception; however it may have an impact on calcium channel opening as 
evident by its effect on time to peak for the calcium transients.  In contrast, ET-1 
induced release of apelin from the skin was sex-dependent with a decrease in 
apelin release following treatment with an ETB receptor agonist in males, but not 
females.  Overall, this data suggests that behavioral desensitization following 
priming with ET-1 may be at the level of the afferent neuron and that if apelin 
modulates this behavioral desensitization it may occur by modifying the skin 
microenvironment and the initial activation of the afferent neurons or potentially 
at the afferent neuron-spinal cord synapse. 
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 The present calcium imaging results demonstrating ET-1 priming induced 
desensitization is supported by previous studies which showed that ET-1 causes 
an increase in [Ca2+]i in neuronal cells, while repeated administration of ET-1 
onto mouse neuroblastoma-rat DRG hybrid cells reduces [Ca2+]i transients (Zhou 
et al., 2001; Yamamoto et al., 2006).  These studies also found that the ET-1-
induced increase in [Ca2+]i is mediated by activation of the ETA receptor (Zhou et 
al., 2001).  However these previous studies also found that the increase in [Ca2+]i  
comes from intracellular stores, while this present study found that this increase 
was due to the influx from extracellular Ca2+.  The difference in the source of 
[Ca2+]i increases in our study and the aforementioned studies may be explained 
by the much larger dose of ET-1 used in our study to prime the cells as well as a 
potential species difference in DRG neurons.  
Depending on the cell type and species investigated, ET-1-induced influx 
of extracellular Ca2+ can be due to direct or indirect regulation of voltage gated 
Ca2+ channels as well as non-selective cation channel and store-operated Ca2+ 
channel activation (Tykocki and Watts, 2010).  In mammalian parasympathetic 
neurons, ET-1 causes an increase in [Ca2+]I by activating receptor-operated Ca
2+ 
channels (Nishimura et al., 1991).  In many cell types, ET-1-induced Ca2+ 
mobilization is caused by a mixture of voltage-dependent Ca2+ influx, voltage-
independent Ca2+ influx, and the release of Ca2+ from intracellular stores (Tykocki 
and Watts, 2010).  One possible explanation for voltage-dependent Ca2+ influx 
due to ET-1 may be the effect of ET-1 on sodium channels.  ET-1, through the 
ETA receptor, lowers the threshold for activation of tetrodotoxin-resistant Na
+ 
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channels in DRG neurons thereby increasing the excitability of the neurons 
(Zhou et al., 2002).  In DRG neurons, ET-1 also enhances neuronal excitability 
by suppressing delayed-rectifier type of K+ currents (Feng and Strichartz, 2009).  
An explanation for voltage-independent Ca2+ influx due to ET-1 may be its effects 
on the opening of cation channels.  In rat glioma cells, the major source of ET-1-
induced increase in [Ca2+]I  was found to be from an influx of extracellular Ca
2+ 
possibly through the opening of non-selective cation channels such as TRPV1 
channels (Lin et al., 1992).   
 Priming with ET-1 also desensitized the [Ca2+]i response to capsaicin, 
which is the chemical found in chili peppers that produces a burning sensation 
when applied externally or ingested.  Capsaicin activates the TRPV1 ion channel 
on DRG neurons, more specifically on small diameter neurons, which leads to an 
influx of Ca2+ (Caterina et al., 1997).  It has been shown that application of 
capsaicin onto DRG neurons causes an increase in [Ca2+]i , while repeated 
applications of capsaicin leads to desensitized response of a reduction in [Ca2+]i 
(Vellani et al., 2001; Yamamoto et al., 2006).  Our result of a decreased 
response to capsaicin in ET-1 primed cells is somewhat in conflict with a 
previous study showing an enhancement of the increase in [Ca2+]i after 
application of ET-1 followed by capsaicin (Yamamoto et al., 2006).  However, this 
difference may be explained by the fact that the neurons used in our study were 
incubated with ET-1 for hours before being removed and challenged with 
capsaicin days later, while the previous published study applied ET-1 seconds 
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before adding capsaicin looking at an acute modulator role versus a long-term 
modulatory role.   
 In our animal model, priming with ET-1 appears to cause a decrease in 
APJ receptor expression in hindpaw skin of male rats, while in the spinal cord of 
male rats, ET-1 priming causes a significant increase in APJ receptor expression.  
The APJ receptor is a G-protein coupled receptor that couples to Gαi/o to inhibit 
the activity of adenylate cyclase (O'Carroll et al., 2013).  When apelin is injected 
centrally into rodents, either intrathecally or intracerebroventricularly, it induces 
anti-nociception through APJ and opioid receptor activation in visceral and acute 
pain models (Lv et al., 2012).  It is possible that long lasting changes induced by 
ET-1 priming cause changes in the expression of APJ receptors in the spinal 
cord due to compensatory mechanisms, which may influence the central 
modulatory role of apelin signaling in nociception.  In isolated skin tissue, 
application of an ETB receptor agonist causes a significant decrease in the 
release of apelin, which was only seen in male rats.  In hindpaw skin of rats, 
activation of ETB receptors causes anti-nociception by causing the release of 
endogenous opioids from keratinocytes, which are then thought to act on 
nociceptors to cause hyperpolarization (Khodorova et al., 2002; Khodorova et al., 
2003).   
 The results of this study suggest that endothelin-induced sensitization 
upon repeated administration may not be occurring at the primary afferent level.  
Furthermore, priming with ET-1 produces a long lasting desensitization of 
afferent neurons to subsequent ET-1 and the alternative algogen capsaicin.  This 
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suggests that behavioral sensitization to repeat ET-1 exposure may be occurring 
in the skin, in the spinal cord, or in the brain.  Future studies are needed to begin 
to understand how the different levels of the pain neuroaxis respond to repeated 
exposure to ET-1.  This preliminary analysis of the apelin system in ET-1 induced 
sensitization/desensitization suggests that in response to endothelin, there is a 
decrease in the peripheral apelin system and a concomitant increase in the 
central apelin system that is sex dependent.  Further studies are needed to more 
fully understand whether apelin plays a significant role in acute ET-1-induced 
nociception or in the ET-1-induced priming effect. 
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Figure 5.1 ET-1-induced increase in Ca2+ due to influx of Ca2+ not from 
release of intracellular stores and priming with ET-1 prevents ET-1-induced 
Ca2+ influx.  Cells incubated in buffer containing Ca2+ exhibited a significant 
increase in intracellular Ca2+ upon treatment with ET-1 compared to cells treated 
with vehicle (p<0.001) when measuring the change in fluorescence (A), the area 
under the curve (B), and the maximum peak height (C). Cells primed with ET-1 
on day 0 then treated with ET-1 at the time of imaging show a significant 
decrease in Ca2+ influx compared to vehicle primed cells treated with ET-1 at the 
time of imaging (p<0.001).  Cells incubated in Ca2+ buffer did not show an 
increase in intracellular Ca2+ upon treatment with ET-1 (A inset).  
  
  
8
2
 
          
 
 
0 50 100 150 200
0
1000
2000
3000
4000
5000
V/V
V/ET-1
Day 0 ET-1/ET-1
Day 1 ET-1/ET-1
Day 2 ET-1/ET-1
Day 3 ET-1/ET-1
Time (sec)
F
-F
o
(a
rb
it
ra
ry
 u
n
it
s)
0 50 100 150 200
0
1000
2000
3000
4000
5000
V/V
V/ET-1
Day 0 ET-1/ET-1
Day 1 ET-1/ET-1
Day 2 ET-1/ET-1
Day 3 ET-1/ET-1
Time (sec)
F
-F
o
(a
rb
it
ra
ry
 u
n
it
s)
A
C D
B
0
500
1000
1500
2000
2500
***
***
**
Veh
Veh
Veh
ET1
 0   1    2     3 Veh
Veh
Veh
ET1
 0   1    2     3
priming day priming day
0.55 M ET-1 5.5 M ET-1
A
U
C
  
(a
rb
it
ra
ry
 u
n
it
s)
0
50
100
150
200
**
*
Veh
Veh
Veh
ET1
 0   1    2     3 Veh
Veh
Veh
ET1
 0   1    2     3
priming day priming day
0.55 M ET-1 5.5 M ET-1
**
T
im
e 
to
 c
al
ci
u
m
 p
ea
k
(s
ec
o
n
d
s)
E
0
100
200
300
400
***
*
Veh
Veh
Veh
ET1
 0   1    2     3 Veh
Veh
Veh
ET1
 0   1    2     3
priming day priming day
0.55 M ET-1 5.5 M ET-1
**
***
M
ax
im
u
m
 p
ea
k 
h
ei
g
h
t
(a
rb
it
ra
ry
 u
n
it
s)
  
83 
Figure 5.2 Time course for prevention of ET-1-induced Ca2+ influx due to 
priming effect of ET-1.  Reducing the priming dose of ET-1 to 2.2 µM reveals a 
particular time course for the decrease in [Ca2+]i.  (A, C) Cells primed with 2.2 µM 
of ET-1 on day 0 and challenged with 0.55 µM of ET-1 on day 4 show a 
significantly smaller increase in [Ca2+]i  compared to cells treated with ET-1 only 
at the time of imaging (***p<0.001) and this level of increase in [Ca2+]i is 
significantly different from vehicle treated cells (**p<0.01).  (B, C)  Cells primed 
with 2.2 µM of ET-1 on day 0 and challenged with 5.5 µM of ET-1 on day 4 show 
a significantly smaller increase in [Ca2+]i  compared to cells only treated with ET-1 
at the time of imaging (***p<0.001) and this level of [Ca2+]i is not significantly 
different from vehicle treated cells.  (D) The time to calcium peak appeared to be 
more rapid for cells treated with ET-1 for the first time on the day of imaging with 
5.5 µM ET-1 compared to cells challenged with vehicle (*p<0.05).  This was also 
true for cells primed with ET-1 on days 0 and 2 and challenged with 5.5 µM ET-1 
(**p<0.01).  (E) Maximum peak height for unprimed ET-1 treated cells and cells 
primed on day 0 and challenged with 0.55 μM ET-1 had significantly greater 
maximum peak heights compared to unprimed vehicle treated cells (***p<0.001 
and **p<0.01, respectively).   
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Figure 5.3 Pre-treatment with ET-1 causes decrease in capsaicin-induced 
influx of Ca2+.  Capsaicin caused a significant increase in [Ca2+]i compared to 
cells treated with vehicle on day 4 (+++ p<0.001) There is a significantly greater 
difference from baseline in capsaicin treated cells primed with vehicle on day 0 
compared to capsaicin treated cells primed with ET-1 on day 4 (***p<0.001).  
There was no significant difference between cells vehicle treated cells primed 
with vehicle on day 0 and vehicle treated cells primed with ET-1 on day 0. 
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Figure 5.4 APJ receptor expression in hindpaw skin and spinal cord of 
postnatal day 11 rats.  (A) No significant differences in APJ receptor expression 
in the male hindpaw were found between the normal (n = 2), saline treated (n = 
9), and ET-1 treated rats (n = 13), but there appeared to be a slight trend for a 
decrease in APJ receptor expression in ET-1 treated rats.  (B) There was a 
significant increase in APJ receptor expression in the spinal cord of male rats 
after treatment with ET-1 (n = 3) compared to saline treated (n = 2) rats 
(*p<0.05).  There is no significant difference in APJ receptor expression in the 
spinal cord of saline (n = 4) and ET-1 treated (n = 5) female rats.
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Figure 5.5 Effect of apelin on ET-1-induced changes in [Ca2+]i (Paradigm 1).  
(A) ET-1 challenged cells.  Cells primed with vehicle or apelin alone had the 
largest changes in fluorescence compared to the ET-1 or ET-1+apelin primed 
cells. (B) Vehicle challenged cells.  There were no significant changes in 
fluorescence in these cells regardless of the priming peptide.  (C) Area under 
curve for F-Fo graphs.  Vehicle primed cells challenged with ET-1 had 
significantly larger AUC compared to all other treatment groups except Apelin/ET 
and ET+apelin/ET treatment groups (*p<0.05 vs. V/ET).  Apelin primed cells 
challenged with ET-1 had significantly larger AUC compared to all other groups 
except V/ET treated cells (+p<0.05 vs. Apelin/ET).  (D) Time to calcium peak.  
Apelin primed cells challenged with ET-1 had significantly longer time to calcium 
peak compared to V/V (*p<0.05) and Apelin/V (+p<0.05) treatment groups. (E) 
Maximum peak height.  ET-1 challenged unprimed cells had a significantly larger 
peak height compared to all other groups except V/V and Apelin/ET treated cells 
(**p<0.01, *p<0.05 vs. V/ET). 
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Figure 5.6 Effect of apelin on ET-1-induced changes in calcium imaging 
(Paradigm 2).  (A) Unprimed cells.  ET-1 causes the greatest change in 
fluorescence. Apelin does not cause an increase in [Ca2+]i and it does not 
enhance ET-1-induced increases in [Ca2+]i.  (B) ET-1 primed cells.  ET-1 causes 
a “desensitized” response in ET-1-primed cells.  The combination of apelin with 
ET-1 causes less of a desensitized response in these cells.  (C) Area under 
curve for both primed and unprimed cells.  ET-1 and ET-1+apelin treated 
unprimed cells have significantly greater AUC compared to vehicle treated cells 
(***p<0.001).  There was a significantly smaller AUC for the ET-1 treated ET-1 
primed cells compared to the apelin+ET-1 treated ET-1 primed cells 
(+++p<0.001).  (D) Time to calcium peak for primed and unprimed cells.  Apelin 
only treated primed cells have a significantly slower time to calcium peak 
compared to cells treated with ET-1 or vehicle (**p<0.01, *p<0.05 vs. 
ET1/Apelin).  (E) Maximum peak height for primed and unprimed cells.  The 
unprimed cells treated with ET-1 or a combination of ET-1 and apelin had a 
significantly greater peak height compared to V/apelin (**p<0.01 vs. V/ET; 
++p<0.01 vs. V/Apelin+ET).  The peak height for these cells was also 
significantly greater than all of the ET-1 primed treatment groups.  
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Figure 5.7 Release of apelin after activation of ETB receptor in hindpaw skin 
of male and female rats.  In the hindpaw skin of male rats, activation of the ETB 
receptor using the agonist IRL-1620 (IRL) leads to a significant decrease in the 
release of apelin compared to the time before and after the application of the 
agonist (*p<0.05).  There was also a significant difference between the apelin 
levels after agonist application in the males and females (*p<0.05).  There were 
no significant differences in the release of apelin between the treatment time 
points for the female rats. 
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CHAPTER 6: 
 
Exploring Apelin Receptor Single Nucleotide Polymorphisms in 
Children with SCD 
  
92 
6.1 Introduction 
 Although the apelin system has not been directly linked to the 
complications of SCD, it has been examined in other pathologies such as 
cardiovascular disease, stroke, and pulmonary hypertension (Hata et al., 2007; 
Sarzani et al., 2007; Falcao-Pires et al., 2009; Jin et al., 2012).  Several single 
nucleotide polymorphisms (SNPs) have been identified for the APJ receptor 
gene, APLNR, and some of these SNPs have been studied for associations with 
some of the aforementioned pathologies.  One study found an association for a 
SNP (rs9943582) found in the 5’-flanking region and the risk for brain infarction in 
a Japanese population (Hata et al., 2007).  Associations have also been found 
between two SNPs found in the 3’-untranslated region (3’-UTR) (rs746886 and 
rs2282623) and blood pressure response to low-sodium intervention in a 
Chinese population (Zhao et al., 2010a).  Using these previous studies, we 
decided to focus on these particular SNPs of the APLNR gene to carry out an 
association study focusing on pain measures in SCD.  We chose these particular 
SNPs because either they had clinical relevance to SCD (brain infarction) and/or 
they had a high minor allele frequency in their respective populations. 
 To examine the apelin system separately in SCD patients, the following 
study explored the associations between the SNPs, rs9943582, rs746886, and 
rs2282623 of the APLNR gene and different pain measures in a pediatric 
population of SCD patients.  In addition to the different pain measures, 
associations between HbF and hematocrit and the different SNPs were also 
explored.   
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6.2 Methods 
6.2.1 Patient medical history and sample collection 
 Saliva samples were obtained from a total of 76 children with SCD 
recruited through the Children’s Center for Cancer & Blood Disorders at Palmetto 
Richland Health Children’s Hospital in Columbia, SC.  Children were excluded 
from the study if they had major developmental disorders or neurologic diseases 
that would result in severe limitations of cognitive ability.  Children were also 
excluded if they were experiencing pain that required opioid usage on the day of 
sample collection.  Children undergoing transfusion therapy were also excluded.  
Demographic as well as pain and disease information was obtained for each 
participant.  The pain history interview consisted of recent pain status (pain 
frequency over the previous year, duration in days, and intensity on a scale of 1 
to 10) and health care utilization (the number of emergency room, 
hospitalizations, or other health care contacts within the last year for patient 
report and past two years for the medical records) was conducted for the child 
and also recorded from the medical records.  A review of the medical records 
was also used to obtain the most recent lab results for HbF and hematocrit. 
6.2.2 DNA extraction 
 DNAzol was added to each sample after collection for preservation and 
stored at room temperature until ready for DNA extraction.  Samples were 
incubated with Proteinase K (20 mg/mL) for at least 12 hours at room 
temperature before extraction.  After incubation with Proteinase K, the mixture 
was transferred to a microfuge tube and centrifuged at 13,000 rpm for 15 minutes 
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at room temperature.  The supernatant was collected and 100% ethanol was 
added, then the mixture was gently mixed.  Samples were allowed to stand at 
room temperature for 10 minutes, and then they were centrifuged at 13,000 rpm 
for 3.5 minutes.  The pellet was collected and 70% ethanol was carefully added 
to the pellet, then the supernatant was removed and discarded.  Deionized water 
was added to the DNA, mixed, then incubated at room temperature for one day, 
then stored at -20°C until PCR amplification. 
6.2.3 Polymerase chain reaction 
 The National Center for Biotechnology Information (NCBI) SNP database 
was used to obtain sequencing information for the SNPs found in the 5’-flanking 
and 3’-UTR regions of the APLNR gene.  The primer sequences (19-20 bases) 
were chosen based on the average GC content and the specific nucleotide 
compositions.  The final primer sequences were chosen after analysis for Tm, 
self-dimerization, hetero-dimerization, and hairpin formation using OligoAnalyzer 
software (Integrated DNA Technologies).  Final primers were purchased from 
Eurofins MWG Operon.  Since the SNPs in the 3’-UTR region were within no 
more than 285 bases of each other, one primer set was designed to amplify 
multiple SNPs within this region (Table 6.1).  The primers designed for the 3’-
untranslated region were originally designed for two SNPs (rs746886 and 
rs2282623); two additional SNPs (rs2282624 and rs2282625) were found in 
these amplified sequences. 
 Each amplification reaction of the SNP in the 5’-flanking region contained 
0.2 µM of each primer, 2.5 mM of each dNTP, 25 mM or 37.5 mM of MgCl2, 1U 
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Taq DNA polymerase, 2.5 µL of ThermoPol buffer (New England Biolabs), 10 
mg/mL bovine serum albumin (BSA), and 1, 2, or 3 µL of genomic DNA in 25, 26, 
or 27 µL reaction volumes.  The PCR amplification conditions consisted of an 
initial denaturation step of 2 minutes at 94°C followed by 37 cycles of 94°C for 15 
seconds, annealing at 53°C for 25 seconds and extension at 72°C for 30 
seconds.  The final extension was at 72°C for 1 minute.  PCR products were run 
on a 0.8% agarose gel to confirm amplification, then stored at 4°C until 
sequencing. 
 Each amplification reaction for the 3’-UTR region contained 0.2 µM of 
each primer, 2.5 mM of each dNTP, 25 mM or 12.5 mM of MgCl2, 1U of Taq DNA 
polymerase, 2.5 µL of ThermoPol buffer, 10 mg/mL BSA, and 1, 2, or 3 µL of 
genomic DNA in 25, 26, or 27 reaction volumes.  The amplification was 
performed at 94°C for 2 minutes followed by 40 or 43 cycles of 94°C for 15 
seconds, 53°C for 25 seconds, and 72°C for 30 seconds.  The final extension 
was set at 72°C for 1 minute. 
6.2.4 DNA sequencing 
 The unpurified PCR products of both the 5’-flanking and 3’-UTR regions 
were sent to High Throughput Genomics Center for Sanger sequencing.  
Sequencher 5.0 (Gene Codes Corporation) or DNA Baser Sequence Assembly 
Software (Heracle BioSoft S.R.L.) was used to determine genotypes from 
sequences. 
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6.2.5 Data analysis 
 GraphPad Prism was used for all statistical analyses.  Chi-square tests 
were used to calculate Hardy-Weinberg equilibrium for each SNP.  A dominant 
model of inheritance, which compares individuals with at least one copy of an 
allele to individuals who are homozygous for the other allele, was used to 
evaluate the associations between the SNPs and the different pain measures 
and a t-test was used to calculate statistical significance.  A t-test was also used 
to determine significance for the associations between HbF and the over-
dominant model, which compares heterozygous individuals to a combined pool of 
homozygous individuals.  A one-way ANOVA followed by a Bonferroni post-hoc 
test was used to determine statistical significance between the different 
genotypes and the pain measures and hematocrit.  A Fisher’s exact test was 
used to determine statistical significance for the associations between ACS and 
the dominant model. 
6.3 Results 
 In our participant population, the rs7446886 and rs2282623 SNPs only 
had a minor allele frequency of 0.0547, so association for these SNPs were not 
pursued.  The following results focus on the rs9943582 SNP found in the 5’-
flanking region and two additional SNPs found in the 3’UTR region (rs2282624 
and rs2282625).  The demographics for these SNPs can be found in Table 6.2. 
These three remaining SNPs were calculated to be in Hardy-Weinberg 
equilibrium (rs9943582, p = 0.9809; rs2282624, p = 1.0000; rs2282625, p = 
0.5088). 
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6.3.1 Associations for the SNPs found in 3’-UTR (rs2282624 and rs2282625) 
 No associations were found between the genotypes of SNPs found in the 
3’-UTR of the APLNR gene and the different pain measures (Figure 6.1).  There 
were also no significant associations found when using a dominant allele model 
for the SNPs (Figure 6.2).  No significant associations were found between the 
presence of at least one copy of the T or A allele and either measure of health 
care utilization (Figure 6.3).  However, there was a trend for an association 
between having at least one copy of the A allele and participant report of health 
care utilization for the rs2282625 SNP where participants with at least one copy 
of the A allele had fewer health care contact than participants who were 
homozygous G (p=0.0852) (Figure 6.3 C). 
 No significant associations were found between the SNPs and the history 
of ACS.  However, there was a strong trend for an association between having at 
least on copy of the T allele for the rs2282624 SNP and ACS, where a lower 
percentage of participants with at least one copy of this allele having a history of 
ACS (p=0.0617) (Figure 6.4).   
 No significant associations were found between hematocrit levels and 
these SNPs (data not shown).  For both SNPs, there was a trend for a decrease 
in HbF levels in the heterozygous individuals (Figure 6.5 A, C).  When an over-
dominant model was applied, there were significant lower levels of HbF in 
heterozygous individuals compared to homozygous individuals for the rs2282624 
SNP (p<0.05) (Figure 6.5 B).  No significant association was found for the 
rs2282625 SNP when this model was applied (Figure 6.5 D).   
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6.3.2 Associations for the SNP in 5’-flanking region (rs9943582) 
 Similar to the previously mentioned SNPs, the SNP found in the 5’-
flanking region of the APLNR gene did not have any associations with any of the 
pain measures using either the three genotypes or the dominant allele model 
(Figure 6.6).  There was a trend for less health care utilization according to 
participant report in homozygous individuals for this SNP (p=0.0993) (Figure 6.7 
A).  This trend was weaker for the health care utilization according to the medical 
records (p=0.1576) (Figure 6.7 B). 
 No significant associations were found between this SNP and the history 
of ACS (data not shown).  There were also no significant associations for the 
levels of hematocrit (data not shown).  There was, however, a trend for an 
association between HbF levels and this SNP with heterozygous individuals 
displaying lower levels of HbF (Figure 6.8 A) and this trend became stronger 
when an over-dominant model of inheritance was applied (p=0.0557) (Figure 6.8 
B). 
6.4 Discussion 
 The results of this study show that while none of the SNPs were 
significantly associated with the direct pain measures of pain intensity, frequency, 
and duration, they seemed to be associated with indirect measures of pain 
correlates such as HbF levels and health care utilization.   
 The APJ receptor gene is found on chromosome 11 in humans and 
encodes a 380-amino acid protein that shares close homology to the Ang II 
receptor type 1a (O'Dowd et al., 1993).  Both the vasodilator effect and anti-
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nociceptive effect come from, at least in part, by the activation of the APJ 
receptor (Ishida et al., 2004).  The rs9943582 SNP located in the 5’-flanking 
region of the gene has been associated with brain infarction in a Japanese 
population (Hata et al., 2007).  This group found that the G allele (the C allele in 
the forward direction) exhibited a higher binding affinity to the Sp1 transcription 
factor and patients who were homozygous for the G allele had an increased 
incidence of brain infarction compared to patient with at least one copy of the A 
(or T) allele.  They also found that the APLNR gene is likely regulated by Sp1 
and postulate that individuals with the G allele have a higher activation of the 
apelin system through the binding of Sp1 to the gene.  The Sp1 transcription 
factor is a DNA binding protein that can either negatively of positively affect DNA 
binding and transcription when phosphorylated (Tan and Khachigian, 2009).  For 
the rat APJ receptor, which shares 90% homology with the human receptor, the 
Sp1 motif in the 5’-flanking region of the gene has been indicated as an important 
regulator of the promoter (O'Carroll et al., 2013). 
 Specifically with the rs2282624 SNP found in the 3’-UTR, there was a 
strong trend for an association with ACS where participants with at least one 
copy of the T allele seemed to be more protected from having ACS compared to 
participants who were homozygous for the C allele.  The 3’-UTR of a gene can 
play an important role in regulating gene expression and this area of the gene 
has been found to be rich in SNPs (Chen et al., 2006).  Even though this SNP is 
not located in a protein coding area of the gene, it may affect the transcription of 
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the APJ receptor in the lungs, thereby having an effect on the development of 
ACS. 
 There was also a significant association for the rs2282624 SNP and HbF 
levels where heterozygous individuals exhibited lower levels of HbF suggesting 
that the heterozygotes are more at a disadvantage than the homozygotes in 
regards to risk factors associated with VOEs.  This association was also seen as 
a strong trend for the 5’-flanking region SNP (rs9943582) and as a weaker trend 
in the other SNP found in the 3’-UTR (rs2282625).  In children, low levels of HbF 
have been associated with an increased risk of ACS, dactylitis, which is painful 
swelling of the hands and feet, and painful crisis, while those with higher levels 
are at a significantly lower risk for these complications (Bailey et al., 1992).  It is 
interesting to note that although these SNPs are located on different regions of 
the gene and do not appear to be linked together, they all display an over-
dominant model of inheritance for this association.  
 Participant report of the frequency of health care utilization within the past 
2 years had somewhat strong trends for association with the rs2282625 SNP 
where individuals with at least one copy of the A allele exhibited a lower 
frequency of health care contacts.  This trend was also seen for the individuals 
who were homozygous for the C allele of the rs9943582 SNP.  Health care 
utilization for patients with SCD is highest among 18-30 year olds, with an 
average 3.61 health care contacts per patient year, compared to those between 
the ages of 31 and 45 (Brousseau et al., 2010).  It has been shown that average 
pain intensity is predictive of health care utilization in SCD patients with higher 
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ratings of pain intensity relating to higher health care utilization (Ezenwa et al., 
2014).  Being able to predict which children will be at an increased risk for having 
greater health care utilization would be of benefit in developing pain management 
plans for when these children leave pediatric care, thereby reducing the high 
costs of hospitalizations associated with this patient population. 
 One important limitation of this association study is the small sample size.  
With a larger sample size, stronger and significant associations may have been 
discovered for the three SNPs and health care utilization and HbF levels.  This 
study would have to be replicated in order to further interpret these results; 
however, these preliminary results suggest that polymorphisms in the APLNR 
gene may be associated with health care utilization and HbF levels in children 
with SCD.  
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Table 6.1 Forward and reverse primers for the SNPs found in the 5’-flanking and 3’-untranslated region of the 
APLNR gene.     
 
 
Region SNP Polymorphism Primer Name Primer Sequence 
PCR 
Product  
 
rs9943582 CT APJR-Forward GGCTGAACATTATCTGTGGT 279 bp 
5’ flanking 
region  
  
APJR-Reverse CCATCCTGCGAAATCTTACA 
  
 
 
                    
3’-UTR rs746886 GA APJR-3UTR-
Forward 
TAGACATCATGCTATCTGC 718 bp 
  
                
 
 
rs2282623 CT APJR-3UTR-
Reverse 
CTTACCCCATCATACTGAT  
 
rs2282624     
 
 
         
 
 
     
 
 
rs2282625 GA    
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Table 6.2 Demographics for rs2282624, rs2282625, and rs9943582 SNPs.  
(A) SNPs (rs2282624 and rs2282625) in the 3’-untranslated region.  (B) SNP 
(rs9943582) in the 5’-flanking region of the APLNR gene.   
Characteristics Column1 N=63 
Age (M, SD) 
 
14.0, 3.3 
Gender (n) 
  Male 
 
37 
Female 
 
26 
SCD Phenotype (n) 
  HbSS 
 
39 
HbSC 
 
16 
HbSb+ 
 
4 
HbSb° 
 
4 
Characteristics Column1 N=60 
Age (M, SD) 
 
14.3, 3.3 
Gender (n) 
  Male 
 
35 
Female 
 
25 
SCD Phenotype (n) 
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Figure 6.1 Associations between pain measures and genotypes for 3’-UTR 
SNPs (rs2282624 and rs2282625).  No associations were found between pain 
intensity (A), frequency (B), and duration (C) and the CC, CT, and TT genotypes 
for the rs2282624 SNPs.  There were also no associations between pain 
intensity (D), frequency (E), and duration (F) for the rs2282625 SNP. 
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Figure 6.2 Dominant T/A model for 3’-UTR SNPs and different pain 
measures.  No associations were found for pain intensity (A), frequency (B), and 
duration (C) and the different genotypes using the dominant T model for the 
rs2282624 SNP.  No associations were for pain intensity (D), frequency (E), and 
duration (F) and the genotypes using the dominant A model for the rs2282625 
SNP. 
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Figure 6.3 Associations for health care utilization (patient report and 
medical records) and 3’UTR SNPs.  No associations were found for health care 
utilization either for (A) patient report or (B) medical records for the rs2282624 
SNP.  There was a trend for an association between patient report of (C) health 
care contacts over previous 2 years and the presence of at least one copy of the 
A allele for the rs2282625 SNP (p = 0.0852).  No significant associations were 
found for this allele and the number of health care contacts from the medical 
records (D). 
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Figure 6.4 Association between history of ACS and the presence of the T 
allele for the rs2282624 SNP.  There was a strong trend for an association 
between the history of ACS and the genotypes for the rs2282624 SNP where 
having the at least one copy of the T allele appeared to be associated with not 
having a history of ACS (p=0.0617). 
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Figure 6.5 Associations between HbF levels and the genotypes or the over-
dominant model for the rs2282624 and rs2282625 SNPs.  (A) No significant 
differences were found between the different genotypes for the rs2282624 SNP, 
but there was a trend for lower levels of HbF in participants with the CT genotype 
(p=0.0962).  (B) When an over-dominant model was employed, there was a 
significant difference between the heterozygous participants and the 
homozygous participants with the heterozygous individuals having lower HbF 
levels for the rs2282624 SNP (*p<0.05). No significant associations were found 
between the genotypes and HbF levels for the rs2282625 SNP (C).  This was 
true even when an over-dominant model was employed (D). 
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Figure 6.6 Associations between genotypes or dominant model for 
rs9943582 SNP and pain measures.  No significant associations were found for 
either of the pain measures, intensity (A), frequency (B), and duration (C) and 
the genotypes.  No significant associations were found for the pain measures, 
intensity (D), frequency (E), and duration (F) and the dominant T model.  
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Figure 6.7 Associations of health care utilization and dominant T allele 
model for rs9943582 SNP.  Although there were no statistically significant 
associations between health care utilization and the genotypes for the rs9943582 
SNP in the 5’-flanking region, there was a trend for and association for 
homozygous CC participants having lower health care contact per the report of 
the participants (A) compared to the participants with at least one copy of the T 
allele (p = 0.0993).  There was less of a trend for this association using the 
medical records of health care utilization (B) (p = 0.1576). 
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Figure 6.8 Associations for HbF levels and genotype or over-dominant 
model for rs9943582 SNP.  (A) There was a trend for lower levels of HbF in 
heterozygous individuals compared to homozygous individuals.  (B) When an 
over-dominant model was applied, this association became stronger (p=0.0557).  
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CHAPTER 7: 
 
Conclusions 
 113 
7.1 Summary of findings 
7.1.1 Specific Aim 1 
 Children with sickle cell disease, a genetic condition characterized by 
changes in hemoglobin which leads to sickling of red blood cells, have frequent 
painful vaso-occlusive episodes which begin early in life and reoccur often across 
the lifespan of the individual.  A major player in these painful vaso-occlusive 
episodes are the balance between vaso-constrictive and vaso-dilatory molecules.  
Endothelin-1 is a major vasoconstrictor that has been shown to be released 
during vaso-occlusive episodes and correlated with pain history.  Apelin is a 
recently identified vasodilatory peptide that also has a modulatory role in pain 
processing.  The goal of this specific aim was to determine the impact of the 
balance between vasoconstrictors (ET-1 and Ang II) and vasodilators (apelin) on 
the pain associated with SCD.  We hypothesized that the ratio between 
vasodilatory (apelin) and vasoconstrictive (ET-1) tone in the vasculature of 
children with SCD may be a marker of pain sensitization and vaso-occlusion and 
that this relationship would be specific for the ratio between apelin and ET-1.  
Plasma endothelin, Ang II and apelin levels were measured following 
venipuncture at routine health visits in children with SCD (ages 2 to 18).  
Procedural pain was assessed via child- and caregiver-reports and observational 
distress.  Pain history was assessed using retrospective chart review.  The 
results of these studies suggest that an imbalance between apelin and 
endothelin systems may be involved in underlying baseline pain and the 
frequency of VOEs.  In contrast, Ang II seems to be correlated with acute 
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procedural pain.  Additional research is needed to understand the role of apelin 
in SCD associated sensitization and Ang II in acute procedural pain in children 
with SCD. 
7.1.2 Specific Aim 2 
Endothelin-1 is a known algogen that causes acute pain and sensitization 
in humans and spontaneous nociceptive behaviors when injected into the 
periphery in rats, and is elevated during VOEs in SCD patients.  The first study of 
this specific aim sought to examine the effect of ET-1 exposure in the neonatal 
period on subsequent contralateral capsaicin-induced secondary mechanical 
hyperalgesia.  ET-1 or saline was injected into the left plantar hindpaw on 
postnatal day 7 (P7).  On postnatal day 11 (P11), capsaicin cream or control 
lotion was applied to the right dorsum hind paw and mechanical paw withdrawal 
thresholds were measured in the plantar hind paw.  In saline control males, P11 
administration of capsaicin produced a secondary mechanical hyperalgesia that 
was still present at 2 hrs.  Neonatal priming with ET-1 did not alter the magnitude 
or the duration of secondary mechanical hyperalgesia in males.  In contrast, in 
control females, P11 administration of capsaicin produced less than 40 minutes 
of mechanical hyperalgesia.  Neonatal priming with ET-1 prolonged the duration 
of secondary mechanical hyperalgesia in females.  Priming with ET-1 on P7 led 
to a significant increase in capsaicin-induced Fos expression in the dorsal horn of 
the spinal cord in both males and females compared to controls (p<0.001) .  
These findings further suggest that pain in early life may alter future responses to 
painful stimuli at both the behavioral and neuronal level.  It also suggest that 
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exposure to ET-1 early in life may alter the processing of future painful insults in 
pathologies that exhibit increased levels of ET-1 such as VOEs experienced by 
SCD patients. 
Previously, our lab has shown that repeated administration of ET-1 results 
in a sex-dependent priming effect, where males display a sensitizing effect to a 
repeat exposure to ET-1 while females display a desensitized effect (McKelvy 
and Sweitzer, 2009).  The second part of this specific aim focused on 
determining if the sensitizing/desensitizing effect of ET-1 occurs at the level of 
the primary afferent neuron.  Calcium imaging using DRG neurons was utilized to 
examine the effects of ET-1 on primary afferent neurons.  DRG neurons were 
isolated from adult male rats and kept in culture for four days to mimic the 
timeline (P7-P11) of our in vivo model.  On the day of culture, cells were primed 
with ET-1 or vehicle, and then on the day of imaging, cells were challenged with 
ET-1, capsaicin, or vehicle.  We found that ET-1 causes a large increase in 
[Ca2+]i in unprimed cells; however, this effect is not seen in ET-1 primed cells 
challenged with ET-1.  This result suggests that at the level of the primary 
afferent neuron, ET-1 priming has a desensitizing effect on subsequent 
exposures to ET-1.  Priming with ET-1 also causes a desensitized response to 
capsaicin compared to unprimed cells challenged with capsaicin, suggesting that 
this priming effect of ET-1 can also extend to other algogens.  This result also 
lends further evidence to the idea that the enhancing effect of ET-1 priming on 
capsaicin-induced secondary hyperalgesia seen in our animal model is likely 
occurring at the level of the spinal cord. 
 116 
The last part of this specific aim sought to determine the effect of 
endothelin system activation on the apelin system in our in vivo as well as our in 
vitro model.  Western blot analysis was used to measure the expression of the 
APJ receptor in our rodent model of an acute VOE in the hindpaw using ET-1.  
Male animals that had been administered ET-1 showed a decrease, although not 
statistically significant, in APJ receptor expression in the hindpaw, while APJ 
receptor expression increased in the spinal cord of ET-1 treated male animals.  
Activation of the endothelin system using an ETB receptor agonist in hindpaw 
skin from male rats causes a decrease in the release apelin; this effect is not 
seen in female animals.  These results suggest that activation of the endothelin 
system causes a decrease in the peripheral apelin system and a concomitant 
increase in the central (spinal cord) apelin system in male animals.  In the 
preliminary study examining the effect of apelin on ET-1-induced calcium 
transients, at the doses used, apelin does not appear to have an effect on ET-1-
induced increases in [Ca2+]i or the desensitizing effect of ET-1 priming. 
7.1.3 Specific Aim 3 
 The purpose of this specific aim was to examine the apelin system in a 
pediatric population of SCD focusing on genetic variability in the APJ receptor 
gene and the association of this variability with pain measures.  To execute this 
aim, DNA was isolated from saliva samples were collected from children with 
SCD, which was then amplified and sequenced.  Three SNPs, two in the 3’-UTR 
and one in the 5’-flanking region were the focus of this association study.  None 
of the SNPs had significant associations with the direct pain measures of pain 
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intensity, frequency, and duration.  However, all of the SNPs showed trends for 
associations between health care utilization and HbF.  The 3’-UTR SNP 
rs2282624 showed a strong trend for an association with a history of ACS.  
Although significant associations were not found between these SNPs and direct 
pain measures, the potential associations with the indirect pain measures of 
health care utilization and HbF levels suggest that further explorations using a 
larger sample size is warranted to help identify potentially vulnerable patients. 
7.2 Limitations 
7.2.1 Specific Aim 1 
 Similar to many human studies, the interpretation for the results in this 
thesis is somewhat limited due to the small sample size studied.  Statistical 
significance was approached for the relationship between several factors for this 
specific aim, and with larger sample sizes, true statistically significant and 
clinically relevant relationships may be revealed.  It is also important to recognize 
that the plasma levels of apelin and endothelin do not necessarily reveal 
accurate tissue levels, which may be more relevant for determining the 
relationship between these peptides and SCD pain. 
7.2.2 Specific Aim 2 
 For the first part of this specific aim (Chapter Four) that examined 
contralateral ET-1-induced sensitization to capsaicin, we recognize that our 
findings are somewhat limited by the lack of knowledge of the specific cell types 
that were found to be activated in the dorsal horn of the spinal cord.  Determining 
these cell types and the mediators involved in this effect of ET-1 may help 
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explain the sex differences found in the effect of contralateral ET-1 priming on 
capsaicin-induced secondary hyperalgesia.  We also cannot rule out the 
possibility that this effect is mediated by supraspinal influences on cells in the 
dorsal horn.   
 For similar reasons listed above, the results of the Ca2+ imaging in vitro 
studies in Chapter Five are somewhat limited because the mechanism of the 
priming effect of ET-1 on calcium transients is currently unknown.  Finding the 
mechanism and receptors responsible for this effect will be important for possibly 
exploring therapeutic strategies in diseases in which ET-1 is known to play a role.  
The interpretation of the results for the study examining the effects of apelin on 
the priming effect of ET-1 is also limited because unlike determining the doses 
for ET-1 and capsaicin, a dose response for apelin was not performed before 
examining its effects.  It is possible that the doses of apelin used in these very 
preliminary experiments may not have been the appropriate doses needed for 
these cell types and assay to reveal the true effects of apelin on ET-1-induced 
calcium transients.  It should also be noted that while our animal models focused 
on neonatal animals of both sexes, our in vitro model only utilized the DRG 
neurons from adult male rats.  Since it has been reported that neonatal and adult 
rat DRG neurons display different calcium currents (Kostyuk et al., 1993), it will 
important to determine if there are age differences in our in vitro model. 
7.2.3 Specific Aim 3 
 The major limitation for this aim was the small sample size used for the 
genetic associations.  Many of the associations found between the SNPs and the 
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different measures approached significance, but did not meet the limit to be 
considered statistically significant.  With a larger sample size, we may be able to 
find more meaningful associations between the SNPs located in the APLNR 
gene and the different measures examined.  Although the SNPs explored in this 
aim were carefully chosen, it is possible that we missed or overlooked SNPs that 
have more of an impact in the pain associated with SCD. 
7.3 Future Directions 
7.3.1 Specific Aim 1 
 This specific aim presented preliminary evidence that suggests that an 
imbalance in the apelin (vasodilatory) and endothelin (vasoconstrictive) systems 
may contribute to the occurrence of VOEs and SCD pain.  This aim also provides 
evidence that both apelin and Ang II significantly decrease with age.  Currently it 
is unknown if the age-dependent decrease in these systems is only seen in this 
disease or if this is a normal occurrence in children without SCD.  It will be 
important to compare the plasma apelin levels found in our pediatric sample to 
race and age-matched controls without SCD to determine if these levels compare 
to the controls.  In adult SCD patients (aged 18-34 years old), during both acute 
crisis and the steady state, there is severe impairment of endothelial function and 
endothelium-independent vasodilation compared to healthy controls (Blum et al., 
2005).  Since adult patients experience these complications as well as 
experiencing more frequent SCD pain compared to children and adolescents with 
SCD (Smith et al., 2008), future studies should examine the levels of apelin, 
endothelin, and Ang II in an adult population of SCD to see if there are further 
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relationships between these mediators in SCD pain.  For future studies, it would 
also be interesting to compare these apelin and endothelin levels found in 
plasma taken during the steady state with levels from healthy controls as well as 
from patients having a VOE to see if levels and ratios change during vaso-
occlusion.   
7.3.2 Specific Aim 2 
 Previous results from our lab examining the effect of repeat exposure to 
ET-1 on localized changes in the skin found that ET-1 causes an increase in ETB 
receptor expression in plantar hindpaw skin of female rats while it decreased ETB 
receptor expression in male rats (McKelvy and Sweitzer, 2009).  The results in 
this specific aim show that at the level of the primary afferent neuron, repeat 
exposures to ET-1 cause desensitization, but the mechanism that mediates this 
effect specifically in our model is unknown.  A previous study using a repeat 
exposure model of ET-1 examined the effects in a very short time span 
(seconds) and found that in this time span, this desensitizing effect is mediated 
by the ETB receptor (Yamamoto et al., 2006).  For future studies, it will be 
important to characterize this mechanism according to receptor and cell types 
involved since our model involves a long term window (days) for this effect.   
In our animal model, the contralateral sensitizing effect of ET-1 resulted in 
an increase in capsaicin-induced c-Fos expression.  Future studies should 
determine the particular cell type exhibiting this increase in c-Fos activation in 
ET-1 primed animals treated with capsaicin in order to characterize this 
mechanism.  Also in our animal model, the apelin system should be fully 
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characterized.  Although this specific aim measured the expression level of the 
APJ receptor in both the spinal cord and hindpaw skin, the location of the 
receptor in these two locations was not examined.  Future studies should focus 
on examining the expression levels of apelin in hindpaw skin, DRG, and spinal 
cords as well as the location of the APJ receptor in the skin and spinal cord in our 
animal model of acute VOEs. 
7.3.3 Specific Aim 3 
 Single nucleotide polymorphisms in the APLNR gene have been 
associated with the risk of stroke (Hata et al., 2007), blood pressure response to 
salt intervention (Zhao et al., 2010a), and the progression of heart failure 
(Sarzani et al., 2007).  The results presented in this thesis present promising 
associations between SNPs in the APLNR gene and health care utilization, HbF 
levels, and ACS.  Future studies could begin to explore SNPs located in the 
apelin gene (APLN), which is located on the X chromosome, to see if they play a 
role in the complications associated with SCD.  Single nucleotide polymorphisms 
in the APLN gene have been found to be associated with blood pressure 
response to potassium (Zhao et al., 2010b) and fasting glucose levels (Zhang et 
al., 2009).  It would also be interesting to do an association study for the 
angiotensin I converting enzyme 2 (ACE2) gene since this is the only known 
enzyme to degrade apelin fragments (Zhao et al., 2010b). 
7.4 Clinical Implications 
 Sickle cell disease is characterized by many complications, but one of the 
most life altering complications is VOEs, which are responsible for 90% of 
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hospital admissions for SCD patients (Ballas, 2005).  It is thought that the 
repetitive VOEs that occur during the first two decades of life is what may serve 
as the precursor to the development of chronic pain later in life in some patients 
(Smith and Scherer, 2010).  It is also thought that neuropathic pain can develop 
in some patients due to previous painful episodes, which may involve either 
peripheral or central sensitization (Smith and Scherer, 2010).  The findings from 
Chapter Four of this thesis provide evidence that exposure to ET-1 during the 
early neonatal period can cause contralateral sensitization later in the neonatal 
period to capsaicin, an acute pain stimulus, through centrally (spinal cord) 
mediated mechanisms, which may involve the process of central sensitization.  
Central sensitization involves neuroplastic changes in the dorsal horn of the 
spinal cord and is thought to be an important process in the transition from acute 
to chronic pain in some pathological conditions (Voscopoulos and Lema, 2010; 
Woolf, 2011).  The findings from Chapter Four also show that pain in early life 
can alter the response to pain later in life, which highlights the importance of 
finding more effective therapies for treating pain during this critical period in 
children with SCD, who may experience repeated VOEs throughout childhood. 
 Since relationships were found between the ratio plasma levels of apelin 
to endothelin and underlying baseline pain and the frequency of VOEs, potential 
treatment strategies for pain in SCD should possibly be targeting both the apelin 
and endothelin systems together rather than targeting either system alone.  One 
surprising finding from these studies is the differential involvements of the 
vasoconstrictors, endothelin and Ang II, in pain in children with SCD.  While 
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endothelin is involved in SCD related pain, Ang II appears to be more involved in 
acute pain, suggesting that pain management plans for children should 
discriminate the cause of pain since these different forms of pain may respond to 
different pharmacotherapy approaches.  The results from the apelin receptor 
gene association study suggest that polymorphisms in this gene may be a 
predictive tool by which to determine which children will be at an increased risk 
for having greater health care utilization, which would be of benefit in developing 
pain management plans for when these children leave pediatric care, thereby 
reducing the high costs of hospitalizations associated with SCD. 
7.5 Conclusions 
The findings in this thesis present preliminary, but novel evidence that the 
newly discovered vasodilatory peptide, apelin may play a role in the underlying 
pain associated with SCD and it is the balance between the apelin and 
endothelin systems that may be one of the mechanisms responsible for this role.  
The involvement of the balance between apelin and endothelin in SCD pain and 
VOEs appears to be specific for endothelin since Ang II is more related to acute 
pain other than the pain associated with SCD and the vasculopathy/endothelial 
dysfunction sub-phenotype of SCD.  The results in this thesis also present 
evidence that activation of the endothelin system causes a decrease in the 
peripheral apelin system while also causing an increase in the central apelin 
system, suggesting that these two systems may interact in our models, but 
further studies are needed to identify these interactions.  Near associations found 
between polymorphisms in the apelin receptor gene and health care utilization 
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and HbF levels in children with SCD further suggest that the apelin system may 
be involved in the SCD related complications.  The results of this thesis support 
the postulates that ET-1 induces sensitization through central mechanisms in the 
spinal cord and that an imbalance between the vasoconstrictive and pro-
nociceptive systems and vasodilatory and anti-nociceptive systems contributes to 
pain associated with SCD. 
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